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ABSTRACT
CANNABINOIDS:
A NOVEL TREATMENT STRATEGY FOR RETINAL
NEURODEGENERATIVE DISORDERS
Sandeep Samudre
Eastern Virginia Medical School and
Old Dominion University, 2007
Directors: Dr. Frank A. Lattanzio Jr., and
Dr. Patricia B. Williams

Synthetic and naturally occurring cannabinoids are known to decrease intraocular
pressure (IOP). Glaucomatous damage to the retina and optic nerve progresses even after
therapy to maintain normal intraocular pressure (IOP). Topical application of
cannabinoids decreases IOP while not affecting blood pressure or heart rate. Based upon
their effects on other tissues, we hypothesize that these analogs reduce IOP and may also
confer direct neuroprotective effects on the retina, possibly via CB1 and/or CB2
receptors. The purpose of this study is to determine if the newly synthesized CB agonists,
lipid soluble 0-1812 (CB 1), and water soluble 0-2545 (CB 1 « 2 ) are potent ocular antihypertensive and neuroprotective.

The IOP effects were tested in a rat glaucoma model, which was created SpragueDawley rats by ligating 3 of 4 episcleral veins. IOP increased by at least 5 mm Hg in the
operated eye, measured via Goldmann tonometry under sedation. Retinal damage was
induced by injecting NMDA (2 ul of 10 mM) intravitreally in Sprague-Dawley rats. In
other groups 0-1812 (2 mM) and 0-2545 (2mM) were co-injected with NMDA.
Electroretinograms (ERG) were recorded at baseline, 1 wk and 2 wk after injection.

Contralateral normal eyes served as controls. After 2 wk, retinas were flat mounted and
stained with H&E.

While both O-compounds showed significant IOP decrease lipid soluble 0-1812
had the most rapid onset. 0-1812 was also effectively restricted a-wave amplitude loss;
0-2545 was less effective. Retinal whole mounts of NMD A alone showed areas devoid
of cells, while those treated with 0-1812 and 0-2545 were intact with an even
distribution of retinal ganglionic cells. Considering both IOP and neuroprotective effects,
lipid soluble 0-1812 was deemed to be most effective.

Co-Directors of Advisory Committee:

Dr. Peter F. Blackmore
Dr. Stephen J. Beebe
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CHAPTER I
INTRODUCTION
Elevated intraocular pressure or ocular hypertension is a major risk factor for the
development of glaucoma. Reduction of intraocular pressure (IOP) retards glaucoma
1 9

progression for both normotensive and ocular hypertensive patients ' . For this reason,
current therapy is dominated by drugs that decrease IOP. Although drugs, such as beta
adrenergic antagonists, carbonic anhydrase inhibitors, and cholinergic, alpha adrenergic
or prostaglandin agonists, are currently prescribed to decrease IOP, they only indirectly
alleviate glaucomatous damage. The causative factor for glaucoma related blindness is
damage to the optic nerve and loss of retinal ganglion cells.
The therapeutic effect of smoking Cannabis Sativa on IOP was first reported in
the early 19th century3. This plant has more than 480 chemical constituents4. Of these, a
group of at least 66 compounds that contain only carbon, hydrogen and oxygen are
known collectively as cannabinoids 5. They represent a promising therapeutic class and
have been proposed as treatment for a wide range of clinical disorders, including
glaucoma. In 1971, Hepler and Frank reported that smoking marijuana lowers IOP by 2530% in a subset of subjects 6. Unfortunately, duration of action after smoking marijuana
was relatively short, about 3-4 hours, but there appeared to be a dose-response
relationship ' . Other ocular effects were conjunctival hyperemia, reduced tear
production and an increase in pupil size 7. Concomitantly there are acute systemic effects

This dissertation follows the style of Investigative Ophthalmology and Visual Science
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induced by smoking marijuana, such as decreased blood pressure and tachycardia . In
addition to decreasing IOP, cannabinoids may also have neuroprotective actions 5 ' 9 .

A major psychoactive constituent of cannabis, delta 9 - tetrahydrocannabinol
(THC), produces many of its effects through activation of cannabinoid (CBi and CB2)
receptors 10. These receptors normally respond to endocannabinoids, endogenous agonists
that are synthesized and released by neurons on demand. Endocannabinoids may function
as neurotransmitters, neuromodulators or synaptic messengers u . CBi receptors are
largely present in brain, spinal cord, and certain peripheral tissues that include lung,
heart, urogenital and gastrointestinal tract and the eye 12~14. Peripherally located CB2
receptors are found in high concentration in cells and tissues associated with the immune
system, such as the tonsils and spleen, as well as in retina 5 .

Following the identification of endogenous cannabinoids and their receptors,
numerous synthetic cannabinoids were synthesized. WIN-55-212-2 is the well-studied
prototype for the aminoalkylindole synthetic cannabinoids that are structurally different
from endogenous cannabinoids. WIN-55-212-2 activates both CBi and CB2 receptors,
albeit with a proclivity for the CB2 receptors n. In normotensive rabbits, a single dose of
either topical or systemic WIN-55-212-2 reduced IOP without apparent ocular toxicity 15,
most likely through effects on CBi receptors 16. Another major group of
endocannabinoids are the eicosanoids, of which anandamide is a prototypic member.
When released in response to insult or injury, these endogenous substances provide
analgesic and neuroprotective effects. Unfortunately, anandamide is rapidly hydrolyzed

3

by fatty acid amide hydrolase terminating its activity. Numerous studies with structureactivity relationships have led to development of novel anandamide analogs, such as O1812.

This dissertation focuses characterization of anandamide analog, 0-1812, and
THC analog, 0-2545, in terms of their IOP reduction potential, neuroprotective effects
and mechanism of action. Topical administration is emphasized to minimize adverse
systemic and CNS effects.

4

CHAPTER II
BACKGROUND AND AIGNIFICANCE
Visual impairment, ranging from decreased acuity to blindness, is a major cause
of morbidity, interferes with activities of daily living, and increases functional
dependence, and is associated with a shorter life expectancy " . Based on the 2000
census data, nearly 0.8% Americans over the age of 40 suffers from blinding disorders
with an additional 2% with low vision. While those over 80 years of age make up 7.7%
of the population, it is estimated that they account for 70% of blindness; this elderly
segment represents the fastest-growing portion of the population20. As average life spans
increase, age-related loss of vision will become a growing concern.

There are a number of causes of low vision and blindness. The most common
among Americans of varying ethnicities are age-related macular degeneration (AMD),
cataracts, glaucoma, and diabetic retinopathy. Of these impairments, vision can be
restored only in cataracts after surgical replacement with a prosthetic intraocular lens.
The others AMD, glaucoma, diabetic retinopathy cause severe retinal damage and present
significant obstacles in their treatment.

Etiology and Pathology of Glaucoma
Glaucoma is the second leading cause of blindness worldwide 5. Over 66.8
million people have the condition, which has caused bilateral blindness in 6.7 million21.
Fewer than 50% of glaucoma patients in first world countries know that they have the

disorder, and even fewer are aware of it in developing countries

. In the US, open-angle

glaucoma is the leading cause of blindness in Hispanics with an added eight-fold increase
in risk of blindness for African Americans 20. Primary open angle glaucoma is the most
common form, presenting with elevated IOP and concomitant retinal damage. Although
the etiology and pathological basis of glaucoma is not yet fully understood22, increased
IOP remains a risk factor but not necessarily the cause. IOP increases when the aqueous
outflow is compromised possibly due to the inhibition of the trabecular meshwork or by
increased production of aqueous humor by the pars apparatus. This leads to a concordant
increase in pressure across the lamina cribrosa and places stress on the axons of the
retinal ganglion cells. While mechanical pressure might cause neuronal damage,
increased IOP is neither necessary nor sufficient to cause neurodegeneration

" . Other

putative causative or contributing factors of glaucomatous neuropathy are local hypoxia
due to a dysfunction in blood-flow regulation, excessive glutaminergic stimulation,
oxidative stress, abnormal cellular pumps, and a compromised immune function 7. In
addition to high IOP (>21 mmHg), risk of developing open angle glaucoma is increased
by age, the ratio of the horizontal and vertical diameters of the optic cup to the optic disc,
family history of open angle glaucoma, and a thin central corneal measurement28"33.

Pharmacologic Therapies for Glaucoma

It has been over a decade since a new class of pharmacologic agents was
introduced for the clinical management of glaucoma

. Currently available therapeutic

approaches for the treatment of glaucoma include prostaglandin analogs, beta-adrenergic
antagonists, alpha-2 adrenergic agonists, carbonic anhydrase inhibitors and cholinergic

6
agonists. Each of these has a well known profile of clinical response and adverse effects.
Even the first line agent for the treatment of glaucoma, timolol, as monotherapy
controlled IOP in only 98 of 155 patients (63.2%) 34 . More recently, in the Ocular
Hypertension Treatment Study, 40% of patients randomized to treatment required more
than one medication to achieve the goal of a 20% reduction in IOP 35. Reduction of IOP
retards glaucoma progression for both normotensive and ocular hypertensive patients ' .
However, the rationale for reducing IOP to manage glaucoma does not adequately
address the need to curtail neuronal loss. There is currently no efficacious treatment that
directly addresses glaucoma induced neuropathy.

Surgical treatment options for Glaucoma

Lowering IOP either pharmacologically or surgically is the mainstay for
glaucoma management. Pharmacological approaches remain the first line therapy in
most cases of glaucoma. When multiple medications are ineffective or not tolerated,
surgical approaches are implemented. Argon laser trabeculoplasty (ALT) is sometimes
used as initial therapy in glaucomatous eyes. In this technique, 40-50 spots with a size of
50 micron are placed radially around the trabecular meshwork with a short-term success
rate of 65 - 97% " . More invasive surgical approaches include trabeculectomy, where
a small portion of the trabecular meshwork is excised, and filtration surgeries, where a
filtration bleb is created. As with all surgical approaches, complications due to wound
healing or bleb failures are common and may require additional surgical interventions.
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Cannabinoids and Glaucoma

For over thirty years cannabinoids have been touted for their potential to decrease
IOP 6. Unfortunately, cardiovascular and psychotropic adverse effects preclude systemic
administration 40'41. Systemic administration of cannabinoids usually produces unwanted
reductions in systolic and diastolic blood pressure, as well as decreased heart rate and
variable changes in pupil diameter 42~44. Moreover, the associated dysphoric psychotropic
effects of these agents are documented45.

Cannabinoids and Neuroprotection

Evidence for the neuroprotective properties of cannabinoids is based on research
using mice and rat models of traumatic brain injury (TBI) 46. In the early post-traumatic
events that follow TBI, ./V-methyl-D-aspartate (NMDA) receptors are activated leading to
the presynaptic accumulation of glutamate and Ca (2+). The NMD A receptor is
ionotropic which allows Na+, K+ and especially Ca (2+) ions to flow in and out of cells.
Over activation of the NMD A receptor by glutamate and NMD A triggers excessive Ca
(2+) entry into the cells disrupting the cellular homeostatic mechanisms targeting the cell
for apoptosis 47"49. In glaucoma, the death of retinal ganglionic cells is proposed to be
mediated by NMDA receptor induced excitotoxicity50. In response to these events,
phospholipase C is activated, followed by the synthesis of diacylglycerol (DAG) and an
endocannabinoid, 2-arachidonoyl glycerol (2-AG). Once 2-AG is released, it selectively
activates cannabinoid receptors type 1 (CB1) to inhibit glutamate and Ca (2+) release,
thereby protecting the neurons from excitotoxic damage. In a similar fashion,

8

anandamide, which is also an endocannabinoid produced on demand, has been
demonstrated to protect rat cerebro-cortical neurons from ischemic damage. However, the
endocannabinoids are hydrolyzed as rapidly as they are produced limiting the duration of
effect.

Evidence for endogenous cannabinoid production in the eye is sparse, although,
the presence of CB1 receptors has been demonstrated in the trabecular meshwork and
ciliary process tissues 13>51"53. Research done in the 1970's indicated severe retinal
damage when monosodium glutamate (MSG) was injected in rat skin and eyes 5 ' 55 . This
damage was similar to that seen in glaucoma patients. Since then, several studies
reported elevated glutamate levels in the vitreous humor as well as retinal Muller cells of
glaucomatous eyes of humans and monkeys. Recently, the neuroprotective effect of the
cannabinoid, delta 9-THC was demonstrated in a rat NMD A model of retinal
neurotoxicity. In his study, El-Remessey induced retinal damage in rats by intravitreal
injection of NMD A followed by intravenous administration of delta 9-THC 23. While
their neuroprotective effect was clearly established, the safety and practicality of
intravenous injection of a cannabinoid is of concern. Delta 9-THC is a potent
psychoactive substance eliciting the characteristic tetrad effects, namely suppression of
spontaneous activity, antinociception, hypothermia and catalepsy56. We believe that it is
possible to circumvent these systemic effects by topical application of cannabinoids. To
date, no reports that establish neuroprotection as a result of topical application of
cannabinoids have been published.

9

Brief History of Cannabinoid Research
Research on eannabinoids dates back to the 1700's, partly due to its extensive
medicinal use in India and the East. Ingredients derived from the plant Cannabis Sativa
were extracted as a resin (hashish) and were widely circulated for recreational purposes.
In academic realms, a quest to identify and isolate the active components had already
begun. In 1855, the Pharmaceutical society of Paris awarded Personne a prize for his
extraction of a volatile oil from hemp 57. This attempt, albeit novel, did not produce
CO

meaningful results, as this oil was inactive and contaminated with toxic terpenes .
Isolation of the active ingredient was complicated by the presence of numerous lipids in
the mixture making the separation tedious and, in most cases, impossible. With
limitations in the isolation techniques, composition of the active ingredient eluded
scholars of the day. It was presumed that the active component was an alkaloid similar to
that of opium 59.

In 1975, the first cannabis alkaloid was identified. Cannabisativine was isolated
form a Mexican variant of Cannabis Sativa. However, this form was still crude, and its
biological activity in man was not established owing to its low concentration in the plant
itself. Meanwhile, Gaoni and Mechoulam, isolated the main psychoactive ingredient,
delta 9-THC using chromatography and NMR 60 . By the late 1970's most eannabinoids
were isolated and a majority of its metabolic pathways defined59. Cannabinoid-based
drugs were developed in the mid 1980's. For example nabilone was approved for use as
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an antiemetic agent in the UK and later dronabinol in France as an appetite stimulant for
AIDS patients61.

Cannabinoid Receptors

The pharmacological basis of cannabinoid action was assumed to be related to
their high lipophilicity. Delta 9-THC is a potent lipophile and its biological activity
considered to be similar to that of anesthetics and solvents. The isolates were racemic
mixtures of delta 9-THC. Progress towards identification of a receptor-based system was
hampered because of the assumption that their mechanism of action was similar to that of
anesthetics rather than a receptor based system. In 1988, using tritium labeled
cannabinoids, Howletts et al., identified a cannabinoid-based receptor. This discovery
was an impetus for subsequently cloning the receptor 62.

Strategies to clone the receptor were based on conserved sequence motifs to clone
G protein-coupled receptors. Using this concept, resultant cDNA clones from rat brain
were screened against its genome resulting in identification of a CB1 receptor specific for
cannabinoids

. This conserved sequence was screened in mouse and human genomes as

well. In both rats and mice, this receptor encodes a protein made up of 473 amino acids
64

. In humans the sequence was identified to be 472 amino acids sharing a 97-99%

sequence identity with rats and mice 65,66. The CB1 receptor is made up of seven
transmembrane domains, resembling G protein coupled receptors in form and function
(signal transduction). The CB1 receptor (mRNA and protein) is predominantly found in
brain and neuronal tissue.
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In 1993, Munro et al. cloned a new receptor from human HL-60 cells that bound
delta 9-THC, aminoalkylindoles and eicosanoids. This 360 amino acid sequence was
markedly different from the 472 amino acid sequence of the CB1 receptor. In fact, it
shared only 48% homology with the CB1 receptor and 70-80% homology with other
species. This new receptor was designated as a CB2 receptor. This receptor contains
seven transmembrane domains and is predominantly found in spleen and immune tissues.
Subsequently, genes for mouse and rat CB2 were cloned 67 ' 68 . It should be noted that the
rat gene is 13 amino acids longer at the carboxyl terminal than the mouse gene.

Considerations for cannabinoid receptor agonist binding

Successful cloning of the CB receptors has spawned numerous efforts to define
agonist binding sites. The CB1 receptors comprised of seven transmembrane helical
domains as well as a well conserved amino terminal extracellular domain containing 117
residues 10. However, this long amino terminal domain does not play a major role in
ligand binding or recognition 69.

Successful binding of anandamide to CB 1 receptor is facilitated by lysine residue
(position # 192) located at the extracellular end of helix three. Substitution of this residue
with alanine eliminated anandamide binding and subsequent receptor activation, but had
no effect on WIN55212-2 binding 16'70. WIN55212-2 is the well-studied prototype for
the aminoalkylindole synthetic cannabinoids that are structurally different from
endogenous cannabinoids. While substitution with arginine had little effect, glutamine

12
eliminated any binding71. The corresponding lysine in CB2 receptors is located at
position 109 on helix three. Substitution of this lysine with arginine or alanine had little
effect on receptor binding .

Selectivity for agonist and antagonist binding can be localized to helices 4 and 5
for both CB receptors. For agonist binding, a residue of interest is tryptophan at the
extracellular end of helix 4. Substitution with alanine or leucine eliminated binding of
most known agonists including WIN55212-2. The effect of anandamide binding was not
studied in this model 10 . Selectivity for antagonist binding (SR141716A, CB1 antagonist)
resides at the beginning of helix 5 68.
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Anandamide
2-AraGhidQriOyi
glycerol

"1

Figure 1: Structure of anandamide and 2-arachidonoyl glycerol (2-AG) 10.
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Structure Activity Relationships
Anandamide is one of five endogenous cannabinoid receptor agonists found in the
mammalian brain 73 . It belongs to the eicosanoid group and characterized by 20:4, n-6
series fatty acid amides (Figure 1) 10 ' 74 ' 75 . The most investigated to date have been
anandamide and 2-arachidonoylglycerol (2-AG) .

Activity of anandamide is similar to that of delta-9-THC in that is a partial CB1
agonist with significantly less affinity for CB2 receptors '

. As a molecule,

anandamide does not contain any chiral centers, a property that can be exploited to
develop potent synthetic agents. Once released, anandamide is rapidly hydrolyzed by
fatty acid amid hydrolase (FAAH) to produce arachidonic acid and ethanolamine. Martin
et al. have proposed the following SAR's for developing potent synthetic CB1 agonists
7Q 8 0

based on the anandamide framework

' :

1) Introduction of a methyl group on the 1 alpha carbon of anandamide resists the
hydrolytic action of FAAH.
2) Substitution of the amide with a two or three carbon chain is a requirement for
activity.
3) Activity is decreased if the hydroxyl is substituted. Substitution of the hydroxyl
with an amino or carboxyl groups eliminates its activity.
4) Metabolic stability is increased by the introduction of a methyl in the primary
carbon adjacent to the carbonyl or nitrogen.
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5) Structural changes in the arachidonoyl and ethanolamide moieties yield highest
potencies.
6) Activity is dramatically reduced if the chain length is decreased by two
methylenes.

Development of O-Compounds

With these structure activity relationships defined, novel cannabinoid compounds,
that are potent and highly selective for the CB receptors were developed by Organix Inc.,
(Woburn, MA), in collaboration with Dr. Billy Martin (Virginia Commonwealth
University - Medical College of Virginia, Richmond, VA). Endocannabinoids like
anandamide are produced in vivo in response to ocular injury but they are rapidly
hydrolyzed by the enzyme FAAH. Anandamide is one of five endogenous cannabinoid
receptor agonists found in the mammalian brain and also the most investigated to date,
along with 2-arachidonoylglycerol (2-AG). Activity of anandamide is similar to that of
delta-9-THC in that is a partial CB1 agonist with significantly less affinity for CB2
receptors 69'76~78. As a molecule, anandamide does not contain any chiral centers, a
property that can be exploited to develop potent synthetic agents. Once released,
anandamide is rapidly hydrolyzed by fatty acid amid hydrolase (FAAH) to produce
arachidonic acid and ethanolamine. The newly synthesized series of O-compounds
include 0-1812 and 0-2545. Compared with anandamide, 0-1812 has higher affinity for
the CB 1 receptor. The methyl substituent in the 1 alpha position reduces its susceptibility
to hydrolysis by FAAH

. Even though 0-2545 is a nonselective with respect to

CB1/CB2 receptors, it has the advantage of being water-soluble.
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Utilizing a metabolically stable anandamide analog, (R)-r-methyl-2'-hydroxyethyl-arachidonamide (Met-anandamide), a l,r-dimethylpentyl-Met-anandamide
construct was created and a cyano group was added to the C-20 atom to create 0-1812
(Figure 2) 7 9 . By incorporating a methyl in the 1' carbon atom, 0-1812 is resistant to
enzymatic degradation by FAAH. A cyano substitution gives 0-1812 a 500 - 1000 fold
increased selectivity for the CB1 receptors over CB2, which is greater than the native
anandamide 79. Anandamide-like cannabinoids, such as 0-1812, resist the development
of tolerance, unlike delta 9-THC, suggesting a unique pharmacology that only partially
overlaps with traditional cannabinoids 81. 0-1812 is also implicated in seizure modulation
as it was determined to be a potent anticonvulsant

.

High lipophilicity associated with delta 9-THC, as well as other synthetic
cannabinoids, is a constraint on solubility of these drugs. Cannabinoids require either
surfactant or a water miscible substance, like albumin or Tween 80, to solubilize 80'83. A
common vehicle used is a mixture of ethanol, Emulphor and saline, but even when
dissolved in this vehicle, the cannabinoids will precipitate 84'85. It is impractical to use
these vehicles in a chronic application scenario as the vehicle itself may contribute to
adverse effects, for example chronic application of ethanol can lead to corneal
debridement when applied topically. To avoid these pitfalls, numerous attempts to create
water-soluble cannabinoids have been made.
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Figure 2: Structures of 0-1812 and methanandamide
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Zitko was successful in his attempt to prepare a water soluble cannabinoid .
Delta 9-THC was converted to a morpholinobutyryl ester and conjugated with
hydrochloride to make it water-soluble. Like its parent compound, this esterified
compound retained its pharmacological activity. More recently, Martin et al. have
developed cannabinoid compounds that are considerably potent than delta 9-THC, more
specifically, 0-2545 87. Commercially available 5-cyano-dimethoxyresorcinol was a
starting ingredient which was converted to a t-butyl dimethylsiloxy derivative and treated
with an imidazole to produce 0-2545 87'88. Substitution with imidazole readily forms
hydrochloride salts making the analogs water soluble and does not require metabolic
conversion to an active molecule like ester analogs

. This substitution also imparts a

high CB1 affinity but even a higher CB2 receptor affinity. When dissolved in saline, O2545 was 40 fold more potent that delta 9-THC and was 20 times less lipophilic than
delta 9-THC 87.
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C H A P T E R III

H Y P O T H E S I S A N D SPECIFIC A I M S

Glaucoma is a group of diseases that cause retinal and optic nerve damage.
Although increased IOP is a contributing factor for glaucomatous damage, many people
develop this damage with normotensive IOP. Although numerous pharmacologic agents
are available to control elevated IOP, none directly address retinal and optic nerve
neuropathy. This dissertation focuses characterization of the anandamide analog, O1812, and THC analog, 0-2545, in terms of their effect on IOP, neuroprotective effects
and the mechanism of action responsible for these effects. Topical administration is
emphasized to minimize adverse systemic and CNS effects.

Preliminary studies/progress report

These studies are designed based upon the suggestion by Green that
endocannabinoids may have neuroprotective effects 42. We employed a novel technique,
the electroretinogram (ERG), to provide in vivo evidence of neuroprotection in a rat
NMDA model that mimics glaucomatous damage.

Functional analysis of the retina through ERG:

In diseases, like glaucoma, where the retinal integrity is compromised, ERG is an
effective tool to assess the onset, severity and quantitate the loss of functional
photoreceptors

. By documenting the retinal response to light stimulation, this method
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can accurately measure the functionality of photoreceptors and supporting retinal cells,
such as amacrine cells. ERG records the electrical response to light stimulus in darkadapted eyes. Electrical responses, indicative of retinal function, are quantified and
recorded electronically resulting in a waveform that is composed of a-waves, b-waves
and oscillatory potentials (Figures 3). The a-wave represents activation of the rods and
the b-wave the cones.

Our preliminary ERG studies demonstrate, a diminished amplitude and
corresponding area of both a- and b-waves after 2 wks of NMD A treatment, synonymous
with glaucomatous damage (Figure 3), which are similar to those reported by Fortune et
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Figure 3: ERG a- and b-waves 2 weeks after NMDA injection.
Animals were dark adapted and stimulated with brief bright light flashes.
Arrows indicate light stimulation.
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Chronic treatment with synthetic cannabinoids:

Our preliminary experiments suggest that over an extended period in an ocular
hypertensive model, topically applied WIN 55212-2 is an effective and non-toxic ocular
hypotensive agent 90. Rats were randomly assigned to either the WIN 55212-2 (Tocris,
Bristol, UK) or vehicle treated group. For 4 weeks the right eye of 5 rats was treated
topically three times per day between 8 AM to 6 PM, with 20 \il of WIN 55212-2 (0.5
%). As a control using the same dosing regimen, 4 other rats were treated with
Tocrisolve™ alone for 4 weeks (vehicle treated group). IOP, heart rate, and blood
pressure were measured weekly, between the first and second daily doses. At the end of 4
weeks, there was a 1-week washout period to determine if IOP returned to baseline. Rats
were allowed to recover without drug or vehicle treatment for 1 week before the final
measurements on week 5.

Baseline IOP was 14.1 ± 0.6 mmHg in the operated eye; BP = 134±8/98±8 mm
Hg; HR = 349±30 BPM. IOP decreased rapidly in the WIN-55-212-2 treated group.
After one week of treatment IOP was 70% of baseline. IOP remained significantly
decreased during the entire topical WIN-55-212-2 treatment period. The maximum
decrease in IOP was seen after 3 weeks of treatment when IOP decreased to 47% of
baseline. IOP returned to baseline (week 5) after the drug was discontinued (week 4) 91'
. The vehicle, Tocrisolve™, alone had no effect on IOP. The cornea, conjunctiva and
anterior chamber were normal with no signs of ocular inflammation. There were no
effects on HR or BP, such as those associated with systemic administration. A more
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comprehensive report ofWIN 55-212-2 effect on IOP after acute and chronic
administration is included in chapter 9.

Experimental design

Specific aim #1: When applied topically, how effectively do cannabinoids penetrate the
ocular structures?

A relatively new method for the elucidation of pharmacokinetic profiles in vivo is
microdialysis. It has been successfully utilized for regional sampling of low-volume
compartments of many tissues, such as the brain, joints, kidney, and eye 93. By removing
a minute amount of aqueous humor and re-perfusing an equivalent volume, microdialysis
sampling allows for serial measurements of the aqueous fluid in order to create a
complete concentration versus time curve for an individual subject. Rittenhouse et al
used microdialysis sampling to produce intra- and inter-animal absorption profiles of
propranolol after topical and intracameral injection, showing it to be an accurate and
easily reproducible method93. In this study, we will use a similar method to examine the
pharmacokinetics of lipophilic and hydrophilic O-compounds after topical ocular
administration in an artificially perfused rat model.

For artificial perfusion, Sprague Dawley rats will be first euthanized, a Y incision
will be made to expose chest cavity. A cannula will be placed in the descending aorta
and all systemic circulation will be blocked except for the internal carotid arteries.
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Perfusion with PBS will be adjusted to maintain a carotid pressure of 90 mmHg. Dialysis
probes will be placed in the anterior and posterior chamber of the perfused animal. The
flow rate for the probes will be 1 ul/min and dialysate samples will be collected every 10
min. Cannabinoid concentration will be quantified by HPLC, using a modification of the
method described by Barberi-Heyob and colleagues, with a 5-um reverse-phase column
(Prodigy 5 um ODS(2) analytical column, 150 x 4.6 mm, Phenomenex, Torrance, CA) at
ambient temperature with a mobile phase of acidified acetonitrile water (pH = 4.0)
solution 94 ' 95 . The flow rate will be 1 mL/min with UV detection (254 nm).
Chromatograms will be analyzed using Beckman System Gold software (Beckman
Instruments, Inc., Fullerton, CA).

Specific aim #2: Do endocannabinoid analogues reduce IOP? What is the preferred
receptor type for this effect?

Hypothesis: In previous experiments with WIN 55212-2 1%, IOP decreased by 30%.
WIN 55212-2 is a mixed CB agonist. Because O-compounds are also CB agonists, we
hypothesize that the O-compounds will be as efficacious as WIN 55212-2 in reducing
IOP.

Null hypothesis: If there is no decrease in IOP, then either the O-compounds are not
efficacious ocular CB agonists or they are subject to rapid degradation i.e. they do not
reach their intended targets at therapeutic concentrations. If this is the case then other
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strategies of drug administration and synthesis of more potent analogs need to be
considered.

To determine the receptor that is responsible for the IOP effect, selective CB1
antagonist, e.g. SR141716A, or a selective CB2 antagonist, e.g. SRI44528, will be used
to block the ocular effects of the agonist. To establish the mechanism of action including
correlation between efficacy and effects on CB1 and CB2 receptors, other rats will be
retreated with either a CB1 or CB2 receptor antagonist before topical treatment with the
nonspecific receptor agonists as described above.

Specific aim #3: Do endocannabinoid analogues confer neuroprotection as reflected by
changes in the ERG? Which receptor (CB1 or CB2) participates in the neuroprotective
effect?

Hypothesis: In the amygdala, CB agonists 0-1812 and 0-2545 are neuroprotective. In
the CNS or in neural tissues, they decrease oxidative damage and also increase neuroglial
proliferation

' . The retinal ganglionic cells are of glial origin and, therefore, we

hypothesize that the retinal ganglionic cells would show similar profiles. However, in the
ocular environment proliferation of the retinal ganglionic cells is not possible due to
physiological constraints. Thus, only the neuroprotective effect of these CB agonists will
be evaluated in our NMDA model.
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Table 1: Experimental Plan
Treatment Group
Untreated Control
Positive Control
0-1812
0-2545

Pretreatment

NMDA

X
X

X
X
X
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Null Hypothesis: If these drugs do not show functional neuroprotection, then the retinal
ganglionic cells have an environmental constraint that restricts them from responding like
their progenitors. Other strategies, such as cell culture experiments, will be needed to
determine if, indeed, the ocular environment is the constraint.

Rats will be randomly assigned to one of 4 treatment groups (Table 1). Some rats
will be pretreated with topical application of either O-1812, a lipid soluble CB analog, or
0-2545, a water soluble CB analog. In our prior experiments with glaucomatous rats,
both significantly decreased IOP. For the two treatment groups, each rat will receive 3
doses at 2 hour intervals before injection of NMD A. Both the untreated control and
positive control will receive phosphate buffered saline (PBS) using the same treatment
regimen.

The primary criterion for assessing neuroprotective effects of CB analogs includes
a significant preservation of the ERG waves. ERG measurements will be performed at
baseline and at 1 and 2 weeks following administration of NMD A. Rats will be sacrificed
after 2 weeks for morphological analysis of the retina including retinal ganglionic cell
counts. Groups treated with CB analogs should have a decrease in IOP without systemic
effects, e.g. stable heart rate and blood pressure.

In the amygdala, 0-1812 and 0-2545 have exhibited neuroprotective effects
through activation of CB receptors 96. In the eye, in addition to the CB 1 receptor, a CB2
receptor is also implicated. If neuroprotection is observed in the eye, then we will
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determine which receptor (CB1 or CB2) is activated to elucidate the mechanism of
neuroprotection.

These experiments will determine whether the effects of each efficacious
cannabinoid are mediated via CB receptors. Receptor activity will be inferred based on
the ability of either a selective CB1 antagonist, e.g. SR141716A, or a selective CB2
antagonist, e.g. SR144528, to block the ocular effects of the agonist. To establish the
mechanism of action including correlation between efficacy and effects on CB1 and CB2
receptors, other rats will be retreated with either a CB1 or CB2 receptor antagonist before
topical treatment with the nonspecific receptor agonists as described above. If
neuroprotection is not mediated via the CB receptor system, then other likely areas of
interest would be to study the antioxidative effects of these drugs.

In addition to the activation of CB receptors, the mechanism of action needs to be
further elucidated by studying Ca [2+] influx into the retinal ganglionic cells. When
NMDA binds to its receptor, it triggers Ca [2+] entry into cell. This produces increased
calcium binding to the intracellular ryanodine receptor-coupled Ca [2+] channel and
subsequent increase in Ca [2+] released from the endoplasmic reticulum (ER). Increased
Ca [2+] will eventually lead to apoptosis (Figure 4). Hypothetically, CB agonists reduce
intracellular Ca [2+], thus mitigating the effects of increased Ca [2+] caused by NMDA.
This effect is mediated via CBl/G-protein coupled inhibition of adenylyl cyclase. In this
preliminary study, the intracellular Ca [2+] will be monitored after treatment with
NMDA only or in the presence of 0-1812 or 0-2545.
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Figure 4: Proposed pathway leading to retinal ganglionic cell loss due to apoptosis.
Arrows indicate site of action for cannabinoids.
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Specific aim #4: Because they have a different mechanism of actions, is there an additive
effect on IOP by combining O-compounds with currently available glaucoma
medications?

As described in the introduction, currently available therapeutic approaches for
the treatment of glaucoma focus mainly on the reduction of IOP. However, up to 50% of
patients cannot be maintained on single drug therapy; most require use of two or even
three drugs to control their IOP 97. Commonly used classes of agents are (3-adrenergic
antagonists (timolol), a-adrenergic agonists (brimonidine), prostaglandins (travoprost)
and carbonic anhydrase inhibitors (dorzolamide). Timolol lowers IOP by decreasing
aqueous humor production while brimonidine, in addition to decreasing aqueous humor
production, has the added benefit of increasing uveoscleral outflow 98 '". Dorzolamide
reduces aqueous humor formation while prostaglandins increases uveoscleral outflow
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. We hypothesize that O-compounds are more efficacious than the currently available

agents.

The primary purpose of this study is to compare efficacy of timolol, dorzolamide
or brimonidine as monotherapy or in combination with endocannabinoid analogs, 0-1812
or 0-2545, in a rat glaucoma model. All drugs will be administered individually and IOP
measured using a Tonolab™, a new instrument specifically designed to measure IOP in
rats and mice. For combination therapy, timolol, dorzolamide or brimonidine will be
administered first followed by 0-1812 or 0-2545. For all conditions, IOP will be
measured 30, 60 and 120 min after drug administration.
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CHAPTER IV
METHODS AND MATERIALS
Animal Subjects
All studies were conducted in accordance with the Principles of Laboratory
Animal Care (NIH Publication No. 85-23, revised 1985), the OPRR Public Health
Service Policy on the Humane Care and Use of Laboratory Animals (revised 1986), the
U.S. Animal Welfare Act, as amended, as well as the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research. Protocols were approved by the Eastern
Virginia Medical School (EVMS) Institutional Animal Care and Use Committee.

Rat Ocular Hypertensive Model

In human glaucoma, a gradual progression of IOP leads to various retinal deficits.
This condition can be mimicked in an animal model by ligation of major outflow vessels.
To elevate IOP, male rats weighing ~ 200 gm (14 Sprague Dawley, 4 Brown Norway, 5
Long Evans and 5 Wistar) underwent vortex vein ligation (Harlan, Indianapolis, IN).
Surgeries were performed on the right eye (OD) while the contralateral left eye (OS)
served as a normal non-operated control. A detailed explanation of the surgical technique
is described in chapter 5, the development of a rat ocular hypertensive model.
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Rat N-methyl-D-aspartate (NMDA) model
As a model to induce reproducible damage to the photoreceptors and retinal
ganglionic cells, male Sprague Dawley rats weighing ~ 200 gm were injected
intravitreally with 2 ul of 10 mM NMDA. All injections were made in the right eye (OD)
while the contralateral left eye (OS) served as a normal non-modified control. In these
experiments only damage to the photoreceptors was measured as a function of ERG awave amplitude. Although retinal damage was evident within 24 hours of NMDA
injection, only 2 week measurements were reproducible.

Measurement of IOP

IOP response is a primary outcome measure for drug efficacy. Although IOP can
be measured with a variety of instruments, accurate measurements can only be obtained
by applanation or direct rebound tonometry. In this dissertation, Goldmann applanation
tonometry and an electromagnetic piston rebound Tonolab® will be used to directly
measure IOP.

Goldman applanation tonometer:

IOP measurements were performed under mild sedation (ketamine 40 mg/kg and
acepromazine 6 mg/kg) with a custom machined Goldmann applanation tonometer.
Two readings per eye were taken at each time interval, and averaged. Although Cohan
and Bohr reported Goldmann applanation in the conscious Brown Norway rat, other
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strains were not as docile

. We found that firm restraint of the conscious rats increased

variability. To reduce the likelihood of erroneously elevated IOP readings secondary to
the Valsalva maneuver, mild sedation was used.

Tonolab®:

In chapter 9, IOP measurements were made with a Tonolab® (Colonial Medical
Supply Co. Inc., Franconia, NH). To reduce the likelihood of erroneously elevated IOP
readings secondary to the Valsalva maneuver, mild sedation was used (ketamine 40
mg/kg and acepromazine 6 mg/kg).

Electroretinogram (ERG)

ERG is a non-invasive measure of retinal function. Damage to the different layers
of the retina can be assessed by quantitating the amplitude of the a-waves (photoreceptors
and bipolar cells) and b-waves (inner retinal function). This test can be performed
photopically (light adapted) or scotopically (dark adapted). Maximal retinal response can
only be obtained scotopically. In this dissertation, scotopic ERG was used to determine
retinal function for the ligated ocular hypertensive model as well as experiments with
NMDA model. Scotopic ERG changes were measured only at terminal points (32 - 72
weeks) in Sprague Dawley rats with sustained IOP elevation (n=10) to determine the
extent of retinal damage. For the NMDA model, ERG's were obtained at 1 and 2 weeks
after NMDA injection. NMDA was also used as a positive control in other experiments,
which reduces the amplitude of both a- and b-waves 89.
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ERG Procedure:

Rats were dark adapted for at least 4 hr. Eyes were dilated with atropine (1%,
Falcon Pharmaceuticals, Fort Worth, TX). To restrict rat mobility, they were
anesthetized with acepromazine (12 mg/kg, IP) and ketamine (80 mg/kg, IP) followed by
topical proparacaine (0.5%) and methylcellulose gel (GPS 2.5%, Wilson Ophthalmic
Corp, Mustang, OK). Custom made AgCl electrodes (Warner Instruments, Hamden, CT)
were placed on the apex of the cornea. Stimuli consisted of 10-usec flashes of
unattenuated white light (30 cd/mm) generated by a Ganzfeld bowl photo stimulator
(Grass Instruments, PS22, Quincy, MA). ERG's were recorded separately in each eye,
while the contralateral eye was covered with an eye patch. ERG responses were
differentially amplified (1-1000 Hz) with a driver amplifier (Grass Instruments, Model
7DAF Polygraph, Quincy, MA). Data were acquired digitally via DASYLab® (Bedford,
NH). The contralateral normal eye served as an age matched negative control, e.g.
response in a normal, undamaged eye. Differences in amplitude of the a- and b-waves
between the operated eye and the contralateral eye were calculated and analyzed.

Fundus Examination

In glaucoma, severe degeneration of the retina and optic nerve contribute to an
increase in the size of the optic cup relative to the optic disc. A fundus examination can
detect changes in the optic cup and disc. With electronic documentation of the fundus,
accurate cup to disc ratios to estimate the severity of glaucoma can be obtained.
Glaucomatous changes in the fundus were observed by slit-lamp examination on
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anesthetized rats. Retinal images were recorded with a 3.2 mega pixel digital camera
(PowerShot SI IS, Cannon, Tokyo, Japan) retrofitted to a slit lamp (Zeiss, Germany).
Full resolution images were obtained with a constant optical zoom (10 X) and processed
with Metamorph™ image analysis software. Cup to disc ratios were obtained for area,
height, and width using Metamorph™ image analysis. For area measurements, the outer
edge of the cup and disc were selected, pixels were counted, and the cup to disc ratio was
determined. For individual height and width cup to disc measurements, diameters for
each was obtained through a central plane. The ratios were then expressed as the cup
diameter to the outer disc diameter.

Assessment for ocular irritation

Assessment of ocular irritation is possible by careful observation of anterior
segment structures with the use of a slit lamp. Each structure of the anterior segment is
evaluated for signs of inflammation and quantitated using a semi-quantitative scale as
developed by MacDonald and Shadduck 103. In our experiments, slit lamp examination
(HAAG-STREIT, Bern, Switzerland) was performed by an independent knowledgeable
observer using a modified MacDonald-Shadduck Semi-quantitative Scale for Ocular
Irritation 104. The exam was conducted at the beginning and end of each experiment to
determine if the topical application of cannabinoids or vehicle caused ocular irritation.
Each eye was assessed for signs of inflammation, conjunctival chemosis/swelling,
conjunctival discharge, aqueous fibrin/flare, loss of the corneal light reflex, obscuration
of iris structures, and corneal opacity/vascularization/staining. They were rated on a 4
point scale where 0 represented normal.
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Confocal Examination

In the past, invasive histological techniques such as scanning electron microscopy
were necessary to obtain detailed corneal (epithelium and endothelium) morphology. As
with any histological technique the tissue has to be excised and longitudinal
measurements are not possible. With confocal microscopy, the cornea can be optically
sectioned making it possible to visualize and electronically document the corneal
epithelium, stroma and endothelium. In addition, this method is non-invasive making it
possible to obtain multiple measurements on the same subject during the study period. In
this dissertation, repeated noninvasive in vivo visualization of cornea and anterior
segment for the presence, location and number of inflammatory cells, as well as fibrin,
hyper-refractile bodies and changes in stromal and endothelial cell morphology was
performed by confocal microscopy (ASL 1000, Advanced Scanning Limited, New
Orleans, LA), documented using a CCD camera (Kappa Opto-electronics Inc, Monrovia,
CA) and recorded with SVO-9500MD VCR (Sony Corporation, Tokyo, Japan). Prior to
applanation, rabbits were sedated with acepromazine, 2.5 mg/kg, and ketamine, 25
mg/kg, plus topical administration of 0.5% proparacaine. A surface scan was performed
to verify proper applanation. Corneal thickness, epithelium, stroma, endothelium and
aqueous chamber were optically sectioned in at least 3 representative areas. Endothelial
cell shape changes, infiltration of inflammatory cells into the corneal stroma and anterior
chamber were documented. At least 4-6 trans-corneal scans were collected for analysis
using the Metamorph® imaging system (Universal Imaging, Downingtown, PA). Three
readings were averaged to calculate corneal thickness.
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Heart rate and blood pressure

Heart rate and blood pressure were used to evaluate potential systemic effects of
topically applied CB agonists and adrenergic antagonists. A standard tail cuff apparatus
was used to measure heart rate (HR) and blood pressure (BP) on sedated rats. A pulse
amplifier (Model 29, IITC, Woodland Hills, CA) was placed in line for digital data
conversion. Data were processed with DasyLab® generated analysis module (Version
6.0, Dasytech, Amherst, NH).

Histology

Histologic examination accurately documents any morphologic changes during
the study period. In this dissertation, histology was performed on retinal flat mounts and
retinal cross sections to obtain RGC counts as an adjunct measure of neuroprotection.

Histology for retinal flat mounts:
Eyes were enucleated and fixed in 10% phosphate buffered formalin (Fisher
Scientific, Fair Lawn, NJ) for at least 1 wk. For retinal whole mounts, retinas were
harvested by bisecting the eyes peri-limbally and removing the anterior segment. The
remaining posterior segment cup was flattened with 4 radial cuts after which the retinal
layer was carefully dissected from the underlying choroid and sclera. The flattened retina
was placed vitreal-side up on glass slides (Fisherbrand Superfrost, Pittsburg, PA),
embedded in Aqua-Mount® (Lerner Laboratories, Pittsburg, PA), and stained with 10 X
dilutions of Hematoxylin and Eosin. For positive identification of RGC, retinal flat
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mounts were compared with cross-sections for cell shape, placement and distribution.
All slides were digitally photographed (Opelco) and quantitatively analyzed with Sigma
Scan (Systat Software Inc., Richmond, CA). Cell counts were performed by
knowledgeable masked observers. For each retina, at least 2 microscopic fields of 50
um2 were captured per quadrant at predetermined distance from the optic cup (200 um).
The total retinal area was approximately 500 um2. RGC counts were averaged for each
field and comparisons made between operated, contralateral control and positive control
NMDA treated eyes. Retinal cell counts are expressed as cells per 50 um2±SD.

Histology for retinal cross-sections:

Operated and contralateral control eyes were enucleated and fixed in 10%
phosphate buffered formalin (Fisher Scientific, Fair Lawn, NJ) for at least 1 week. For
retinal cross sections, whole eyes were embedded in cryo media (Tissue-Tek® O.C.T.
Compound, Sakura, Torrance, CA). Sections of 40 um thickness, at the level of the optic
nerve head, were cut and mounted on superfrost glass slides (Fisherbrand Superfrost,
Pittsburg, PA), and stained with hematoxylin and eosin. The slides were digitally
photographed at 20X magnification. Retinal ganglionic cell counts were performed on
200 um sections of the retina, for a total retinal length of approximately 12 mm
documented at 20X magnification. Retinal cell counts are expressed as cells per 200 um
± SD. All quantitations were performed with SigmaScan® (Systat Software Inc., San
Jose, CA)

RGC-5 Cells
RGC-5 Cells were obtained from Dr. Neeraj Agarwal, University of North Texas
Health Science Center, Fort Worth, TX. They are retinal ganglionic cells isolated from
Sprague Dawley rat retinas and then transformed into a \|/2 El A viral vector. The
transformed RGC-5 cells share similar characteristics with native RGC cells in that they
express Thy-1 and Brn-3C and are sensitive to glutamate excitotoxicity and neurotrophin
withdrawal105.

Ca [2+] Measurements

Glutamate excitotoxicity induced by NMDA causes cells to mobilize Ca [2+] and
initiate the apoptosis pathway. It is hypothesized that cannabinoids prevent the
mobilization of Ca [2+] thereby preventing cellular apoptosis. Measuring Ca [2+] influx
in the retinal cells is therefore necessary to understand the mechanism of action of the
cannabinoids. RGC-5 cells were plated on a 96 well plate (BD Falcon, Franklin Lakes,
NJ) until confluent. All cells were then treated with NMDA (ImM). After NMDA
treatment, some cells were incubated with 10 uM of either O-1812 or 0-2545 for 1 hr.
Intracellular calcium was measured using fura-2/AM (Molecular Probes, Eugene, OR).
Cells were loaded with fura-2 (2 mM) at the beginning of the experiment and Ca [2+]
measurements were made at baseline, 30 and 60 min after drug treatment using a
SpectraMAX™ Gemini (Sunnywale, CA) spectrofluorometer (excitation wavelength of
340 nm and 380 nm and an emission wavelength of 505 nm). At the end of the
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experiment, all cells were incubated with, A23187 (Calcimycin, Cole Parmer, Vernon
Hills, IL) a calcium ionophore, after which a final Ca [2+] measurement was made.

Materials

0-1812 and 0-2545 were obtained from Dr. Billy Martin, Virginia
Commonwealth University, Richmond, VA. 0-1812 was directly dissolved in
Tocrisolve™, a proprietary 1:4 soya oil/water emulsion (vehicle, Tocris Bioscience,
Bristol, United Kingdom). 0-2545 was dissolved in phosphate buffered saline. Sutures
were obtained from Sharpoint (Reading, PA). Timolol was purchased from Falcon
(Napa, CA). WIN55212-2 was directly dissolved in Tocrisolve™, as was the CB1
antagonist, SR141716, and the CB2 antagonist, SR144528. SR141716 and SR144528
were generously supplied by the National Institutes of Health (Bethesda, MD).
Travatan® (travoprost, 0.004%, Alcon, Fort Worth, TX), Trusopt® (dorzolamide, 2%,
Merck & Co Inc., West Point, PA), and Alphagan® (brimonidine, 0.1%, Allergan, Irvine,
CA) were donated by the Lion's Eye Clinic, Norfolk, VA.
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Statistical Analysis

Student's t-test was used to compare data from RGC cell counts and changes in
the HR, BP and ERG amplitude. A one-way ANOVA analysis was performed to
compare IOP between treatments with 0-1812, 0-2545, WIN55212-2, timolol. Other
statistical tests are specified in the results section. A difference ofp < 0.05 was
considered statistically significant. All values reported as mean ± SD unless otherwise
noted.
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CHAPTER V
DEVELOPMENT OF A RAT OCULAR HYPERTENSIVE MODEL
Introduction

As previously noted, it is widely accepted that an increase in IOP is a major risk
factor for primary open angle glaucoma 106. Despite some recent evidence to the contrary,
the therapeutic interventions proven to consistently retard the progression of glaucoma
are those that decrease IOP 107~110. To study newer pharmacologic interventions, a valid
experimental model should mimic both pathologic and physiologic characteristics of
glaucoma, including sustained elevated IOP with evidence of retinal damage.

Most published animal glaucoma models elevate IOP only transiently and are
therefore not suitable for long-term pharmacokinetic and pharmacodynamic studies
(Table 2). Transient rapid IOP elevation is less characteristic of primary glaucoma,
where gradual changes in IOP, retinal function and optic nerve morphology are
pathognomonic. Currently available approaches to gradually increase IOP include
occlusion of aqueous humor outflow by laser treatment of the trabecular meshwork,
repeated intracameral injection of hyaluronic acid, injection of hypertonic saline or
cauterization of the vortex veins (Table 2). With these approaches, a primary limiting
factor is a short-lived IOP elevation that does not mimic the common clinical course,
rendering these models unsuitable for long term studies.
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The purpose of the present study was to devise a surgical technique that provided
a constant, long term IOP elevation with concomitant evidence of retinal and optic nerve
damage. We hypothesized that by minimizing surgical trauma during exposure and
ligation of the vortex veins, a stable ocular hypertensive rat model suitable for long term
pharmacodynamic and pharmacokinetic studies can be obtained. Further, we
hypothesized that differences in strains might contribute to differences in the magnitude
and duration of IOP elevation. Four strains of rats, Sprague Dawley, Brown Norway,
Long Evans and Wistar, were compared to determine if some strains were more suitable
models than others.
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Table 2: Review of techniques to elevate IOP

IOP
Measuring
device
Tono-Pen

Baseline
IOP
mmHg
11.9±.9

A IOP
mmH
8
10

Brown
Norway
Brown
Norway
Brown
Norway

Tono-Pen

10-70

7-28

Duration Author
(d, wk,
or mo)
Benozzi etal. 111
5d-10
wk
Morrison et al.
7-34 d

Tono-Pen

19.5±2.8

15

39 d

Johnson etal. 113

Tono-Pen

20.5±.5

-32

34 d

Jiaetal.114'm

Brown
Norway
Brown
Norway
Wistar

Tono-Pen

NR*

13±7

2 mo

Chauhan etal. 116

Tono-Pen

29

10

5 wk

Fortune etal. 89

Tono-Pen

19.4 ±2.1

11-22

9wk

Levkovitch-Verbin
etal. 117

Wistar

Tono-Pen

15.8±.6

14

2 mo

WoldeMussie et
al.118

Wistar

Tono-Pen

16

16

3 wk

Hare etal. l i y

Wistar

pneumo

11±05

5.9

8d

Karim etal. 120

Wistar

pneumo

14-15

10

4wk

Ueda etal. 121

Wistar

pneumo

11.5±.9

8

3 mo

Sawada etal. 122

Brown
Norway
Wistar

Tono-Pen

25.1±0.5

9

8wk

Grozdanicet. al. '

Method

Strain

Hyaluronic
acid
Hypertonic
saline

Wistar

Laser

Laser +
India ink

Cautery3 veins

Ligation

Sprague
Dawley
Wistar

124

Tono-Pen

12-22

>36

3 mo

Mittag etal. 125

Goldmann

15.2±1.6

5.4±1

4 wk**

Hosseini et al.90

Tono-Pen

21.0±1.8

9

7 mo

Yuetal. 126

* NR = not reported
** Duration of the study was 4 wks but IOP was maintained for over 40 weeks in these
animals
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Experimental Design

Animal Model

Male rats weighing ~ 200 gm (14 Sprague Dawley, 4 Brown Norway, 5 Long
Evans and 5 Wistar) underwent vortex vein ligation (Harlan, Indianapolis, IN). Surgeries
were performed on the right eye (OD) while the contralateral left eye (OS) served as a
normal non-operated control.

Surgical Procedure

Rats were anesthetized with acepromazine (12 mg/kg, IP, Boehringer Ingelheim
Vetmedica, Inc., St. Joseph, MO) and ketamine (80 mg/kg, IP, Phoenix Scientific, Inc.,
St. Joseph, MO) followed by topical proparacaine (0.5%, Wilson Ophthalmic Corp,
Mustang, OK) and a lateral canthotomy was performed. After visually identifying the
vortex veins through the conjunctiva and overlying rectus muscles, Westcott scissors
were used to incise only conjunctiva immediately surrounding the vein. Minimal blunt
dissection was performed to isolate the vessel from Tenon's capsule. Once exposed, the
vessel was ligated with 9-0 nylon suture. Distention of the vessel indicated a complete
ligation. The same procedure was repeated on two other vortex veins. The canthotomy
was closed using 7-0 silk suture with prophylactic topical administration of tobramycin
(0.3 %, Bausch & Lomb Pharmaceuticals, Inc., Tampa, FL) and loteprednol (0.5%,
Bausch & Lomb Pharmaceuticals, Inc., Tampa, FL). Buprenorphine (0.05 mg/kg, IP,
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Benckiser Pharmaceuticals, Inc., Richmond, VA) was administered immediately after
surgery and 24 hr afterwards. Sham surgeries were performed in Sprague Dawley rats
(n=4) where, after lateral canthotomy, the veins were exposed but not ligated. Surgeries
on New Zealand White Rabbits were performed in a similar fashion.

IOP was measured using_Goldmann applanation tonometry was employed using a
custom machined applanator (Haag-Streit, Bern, Switzerland). Measurements were made
at the same time of day and by the same observers. IOP measurements reported are
averages of two consecutive readings. Baseline IOP was measured on three separate
occasions during the week before surgery. Based on the rate of increase and sustained
elevation of IOP in Long Evans and Sprague Dawley rats, IOP was measured weekly in
other strains for 4 weeks and monthly thereafter. Rats were lightly sedated with ketamine
(20 mg/kg) and acepromazine (3 mg/kg). Although Cohen and Bohr reported Goldmann
applanation in conscious Brown Norway rats, other strains were not as docile 102. In their
protocol, firm restraint was required which decreased the reproducibility of the
measurements. In our series, however, even mild sedation was not without risk as
mortality related to repeated sedation occurred in four of 14 Sprague Dawley rats over a
40 week period; one of four Brown Norway rats over 16 weeks, and one of five Long
Evans rats over a 6 week period.
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Primary Outcome Measure

Rats with a consistent difference of >5 mm Hg between the operated eye and the
contralateral control eye were included in the study.

Treatment with Timolol

In the rats with sustained ocular hypertension, the response to standard
antiglaucoma therapy was measured. Rats with ocular hypertension, sustained for at least
6 weeks, were treated with a single topical administration of 20 ul of timolol (0.5%,
ISTA Pharmaceuticals Inc., Irvine, CA) to the hypertensive eye. IOP in the treated eye
and in the untreated normal contralateral eye was measured every 30 minutes over a 2 hr
period.

Scotopic ERG changes were measured only at terminal points (32-72 weeks) in
Sprague Dawley rats with sustained IOP elevation (n=10) to determine the extent of
retinal damage. Rats were dark adapted for at least 4 hr. Eyes were dilated with atropine
(1%, Falcon Pharmaceuticals, Fort Worth, TX). Rats were anesthetized with
acepromazine (12 mg/kg, IP) and ketamine (80 mg/kg, IP) followed by topical
proparacaine (0.5%) and methylcellulose gel (GPS 2.5%, Wilson Ophthalmic Corp,
Mustang, OK). Custom made AgCl electrodes (Warner Instruments, Hamden, CT) were
placed on the apex of the cornea. Stimuli consisted of 10-usec flashes of unattenuated
white light (30 cd/mm) generated by a Ganzfeld bowl photo stimulator (Grass
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Instruments, PS22, Quincy, MA). ERG's were recorded separately in each eye, while the
contralateral eye was covered with an eye patch. ERG responses were differentially
amplified (1-1000 Hz) with a driver amplifier (Grass Instruments, Model 7DAF
Polygraph, Quincy, MA). Data were acquired digitally via DASYLab (Bedford, NH).
The contralateral normal eye served as an age matched negative control, e.g. response in
a normal, undamaged eye. Differences in amplitude of the a- and b- waves between the
operated eye and the contralateral eye were calculated and analyzed. As a positive
control, other rats (n = 8) were injected intravitreally with N-methyl-D-aspartate (2 ul of
lOmM NMDA), which reduces the amplitude of both a- and b-waves, and ERG's were
on

obtained 2 weeks later as described above .

Histology was performed on_Operated and contralateral control eyes, which were
enucleated and fixed in 10% phosphate buffered formalin (Fisher Scientific, Fair Lawn,
NJ) for at least 1 week.

Glaucomatous changes in the fundus were observed by slit-lamp examination on
anesthetized rats. Retinal images were recorded with a 3.2 mega pixel digital camera
(PowerShot SI IS, Cannon, Tokyo, Japan) retrofitted to a slit lamp (Zeiss, Germany).
Full resolution images were obtained with a constant optical zoom (10 X) and processed
with Metamorph™ image analysis software. Cup to disc ratios were obtained for area,
height, and width using Metamorph™ image analysis. For area measurements, the outer
edge of the cup and disc were selected, pixels were counted, and the cup to disc ratio was
determined. For individual height and width cup to disc measurements, diameters for
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each was obtained through a central plane. The ratios were then expressed as the cup
diameter to the outer disc diameter.

A standard tail cuff apparatus was used to measure heart rate (HR) and blood
pressure (BP) on sedated rats. A pulse amplifier (Model 29, IITC, Woodland Hills, CA)
was placed in line for digital data conversion. Data were processed with a DasyLab
generated analysis module.

Student's t-test was used to compare data from RGC cell counts, treatment with
timolol, and changes in the HR, BP and ERG amplitude. A one-way ANOVA analysis
was performed to compare IOP, heart rate and blood pressure over time between strains.
Other statistical tests are specified in the results section. A difference ofp < 0.05 was
considered statistically significant. All values reported as mean ± SD unless otherwise
noted.

Results
Development of Ocular Hypertension

Ocular hypertension was achieved by ligating two superior (temporal and nasal)
and one inferior temporal vortex veins. Ligation of all four vessels resulted in pan
vascular rupture in the anterior chamber and was not desirable. No differences were
noted when the position of the ligatures was changed, for e.g. two inferior (temporal and
nasal) and one superior (temporal or nasal) (data not shown). However, the superior
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nasal vessel was preferred over the inferior nasal due to the presence of the nictitating
membrane in this aspect and also because of its ease of access. The primary outcome
measure for ocular hypertension was a consistent difference of at least 5 mm Hg between
the operated eye and the normal contralateral eye. In all strains of rats, this benchmark
was achieved between 1 and 4 weeks following surgery. In the week following surgery,
post-surgical inflammation was occasionally noted, which resolved after treatment with
topical antibiotics and steroids. No signs or symptoms of inflammation persisted beyond
one week. Animals were removed from the study only due to failure to meet
hypertensive criteria for more than two consecutive weeks or to adverse effects of
sedation.

Sprague Dawley Rats

Sprague Dawley rats developed ocular hypertension within one week of surgery
(Figure 5). Although the contralateral control was elevated at one week, it returned to
baseline measurement by two weeks and remained constant throughout the study period.
At two weeks, IOP in the operated eye was significantly elevated to 17.0 ±2.1 mmHg
from a baseline of 9.6 ± 0.6 mmHg. In the initial group (n=5), all rats developed ocular
hypertension and remained elevated past 6 weeks. This surgery was repeated in another
group (n=9) with a total of 14 rats, out of which only one was removed from the study
due to failure to meet the hypertensive criteria for two consecutive weeks. Ocular

hypertension in Sprague Dawley rats remained for 40 wks. In sham-operated animals
(n=4), IOP remained at baseline value of 11.0 ± 1.2 mmHg to 11.3 ± 1.0 mmHg four
weeks later with no IOP changes in the contralateral eye.
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Figure 5: Vortex vein ligation in Sprague Dawley rats.
Week 0 represents baseline presurgical IOP. By 2 weeks after surgery IOP, measured
with Goldmann tonometer, was significantly elevated (p<0.05, n=13). IOP remained
significantly elevated over 40 weeks (p<0.05) maintaining a >5 mm Hg increase over the
contralateral control eye. All controls used in this experiment were unoperated
contralateral eyes. All pair wise comparisons conducted using the Student's t-test.
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Figure 6: Vortex Vein ligation in Brown Norway rats.
IOP was significantly elevated in operated eyes by 3 weeks following surgery (p<0.05,
n=4). However after 15 weeks IOP gradually decreased and no significant IOP elevation
was seen after 34 weeks in the operated eye compared to contralateral control eye. All
pair wise comparisons conducted using Student's t-test.
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Weeks

Figure 7: Vortex vein ligation in Long Evans rats.
Long Evans rats showed a rapid response to episcleral vein ligation as IOP was
significantly elevated by 1 week (p<0.05, n=5). Operated eyes maintained a > 5 mm Hg
increase over contralateral control eyes for 6 weeks (p<0.05). However, measurements
were suspended after 6 weeks due to persistent, rapidly progressing conjunctival
vascularization. All pair wise comparisons conducted using Student's t-test.
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Brown Norway Rats

Three weeks following surgery, IOP was significantly elevated in Brown Norway
rats to 10.5±1.8 mmHg from a baseline of 6.8±0.1 mmHg (Figure 6, n=4). Peak IOP at
15 weeks was 16.1±1.3 mmHg but was not maintained afterwards. Fifteen weeks after
surgery, one rat failed to meet the inclusive criteria and by 35 weeks none met the
hypertensive criteria. No significant anatomical differences were seen in Brown Norway
rats as veins were easily located lateral to the rectus muscles and were similar in size and
shape to the Sprague Dawley rats.

Long Evans Rats

In Long Evans rats, ocular hypertension developed within one week (Figure 7, n =
5). By 3 weeks one rat failed to meet the criteria for ocular hypertension. While all Long
Evans rats developed ocular hypertension, IOP remained elevated for only 6 weeks. Of
particular note was the development of rapidly progressing conjunctival vascularization,
even when subjected to minimal surgical manipulation. Within 6 weeks, this
vascularization had extended to the limbus resulting in the termination of the study.
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Wistar Rats

Vortex vein ligation in Wistar rats was met with several surgical complications.
Significant anatomical differences, mainly, their smaller sized globes and difficulty in
locating the vortex veins contributed to these failures. Due to these reasons the surgical
procedure was slightly modified to include cauterization of the veins. Even after this
modification, the change in IOP did not meet the criteria for ocular hypertension and was
inconsistent and short-lived. After one week IOP increased from 10.5±1.7 mmHg to only
11.5±0.7 mmHg. By week 4, IOP was 13.1±3.2 mmHg in two rats. However, all rats
gradually succumbed to sedation related respiratory complications and died within 6
weeks. During autopsy, numerous collateral arteries bypassing the ligation were noted.

Heart rate and blood pressure

Heart rate and blood pressure were measured in each strain of rats before
surgery (e.g. baseline) and in the weeks following surgery. Four weeks after surgery,
heart rate and blood pressure were unchanged from the presurgical baseline with one
exception (Table 3). Systolic blood pressure was significantly increased in the Long
Evans rats and diastolic pressure tended to decrease. There were differences between the
strains, but they were strain specific since these differences were reflected in baseline
data. For example, presurgical heart rate in Long Evans rats was significantly higher than
in the other three strains.
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Table 3: Heart rate and blood pressure measurements in rats
Rat Strains

Systolic BP
mmHg
120.2 ±15.0
134.2 ±38.3

Diastolic BP
mmHg
94.6 ±14.7
94 A ±44.6

N

Sprague
Dawley

Postop
Preop

Heart Rate
bpm
423.4 ±39.7
383.1 ±97.1

Brown Norway

Postop
Preop

412.8 ±20.8
409.5 ±22.9

119.7 ±16.5
118.4 ±15.0

94.4 ±12.1
94.6 ±8.3

4
3

Long Evans

Postop
Preop

498.3 ± 17.3 f
508.6 ±34.2

156.8 ± 6 . 6 $
137.1 ±5.3

104.3 ±6.9
115.7 ±10.2

4
4

Heart rate and blood pressure remained constant for each strain for the
duration of the experiment; preop values were not obtained on all rats.
Postop = 4 weeks after surgery in the presence of elevated IOP
f significantly different from other strainsp < 0.05.
% significantly different from baseline,/) < 0.05.

7
4
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Electroretinogram (ERG)

Sprague Dawley rats with sustained ocular hypertension were examined by ERG
and fundus photography to ascertain whether the sustained increase in IOP resulted in
glaucomatous changes to the retina. ERG's were performed on both eyes at terminal
points (32 - 72 weeks). The amplitudes of the a-wave and b-wave in the hypertensive eye
were compared with the contralateral normotensive eye. While no ERG aberrations were
seen up to 12 weeks, after 30 weeks the a-wave amplitude significantly decreased by
45.9±22 % (p = 0.03) and the b-wave by 34.9±24% (p < 0.03) from that measured in the
normotensive contralateral eye (n=13). Statistical analysis revealed close correlations
between the amplitudes of the a- and b-waves with both IOP and retinal ganglionic cell
loss (Table 4).

In normal rats, injection of NMD A diminished the amplitude of both a- and fawaves in a manner similar to the surgically ligated eyes. Two weeks after injection, the awave amplitude significantly decreased to 55±0.6% (p < 0.002) of the preinjection
amplitude. Concomitantly, the b-wave amplitude decreased to 49±0.8% (n=8, p = 0.02).
The ERG wave amplitude in the contralateral control eye did not deviate significantly
throughout the observation period (p<0.521).
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Table 4: Correlation analysis of ERG amplitudes (a- and b-wave), increased IOP and
RGC loss.

a-wave
r2

b-wave
P

r2

P

Increased
IOP

0.992

<0.001

0.992

0.008

RGC loss

0.945

0.05

0.829

0.008
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Histology
Representative retinas from Sprague Dawley rats with sustained ocular
hypertension were analyzed for morphological changes. The retinal cell counts were
obtained from retinal cross-sections at the optic nerve level. Three of 14 ligated eyes
with sustained IOP elevation were sectioned. While the overall retinal thickness
remained constant in the ligated and control eyes, reduction in density of the inner and
outer plexiform layers, and the retinal ganglionic layers was noted in the ligated eyes.
Retinal ganglionic layer cell density was significantly reduced to 46.5 ±3.9 (cells per
200um) compared to 62.5 ± 4.5 in the contralateral control, a 26% reduction (p<0.05). A
significant correlation between increased IOP and RGC loss was noted (r2 = 0.946, p =
0.05). Further, the ganglionic cell layer (GCL) appeared to be disrupted in the ligated
eyes (Figure 8a) compared with the contralateral (control) eye, where all the retinal layers
were intact (Figure 8b). In retinal cross-sections, significant cupping was observed in 3
of 4 ligated eyes (Figure 9a) compared to the contralateral control (Figure 9b). Also,
enlargement of choroidal vessels was noted in all ligated eyes analyzed (Figure 10a)
compared to the contralateral control (Figure 10b). No iris synechia or profound angle
closure was seen in hypertensive eyes.

Figure 8A

Figure 8B:
Figure 8: Representative retinal cross sections of ligated and contralateral control eyes at
the level of the optic nerve.
All sections were digitally photographed at 20X magnification. GCL - ganglionic cell
layer, IPL - inner plexiform layer, INL - inner nuclear layer, OPL - outer plexiform
layer, ONL - outer nuclear layer, OS- outer segments. A. Operated eye. B. Contralateral
control eye.

Figure 9A:

Figure 9B:
Figure 9: Retinal cross-sections representing cupping of the optic disk.
A. Cupping in the ligated eye. B. No cupping in the contralateral control eye.
Histological analysis was performed 32-72 weeks after ligation surgery. All
were digitally photographed at 20X magnification.
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Figure 10A:

Figure 10B:
Figure 10: Anterior segment analysis of Sprague Dawley rats that have maintained IOP
elevation past 32 weeks.
Although no iris synechia or profound angle closure was observed, significant choroidal
vessel dilation was present in ligated eyes (A) indicated by arrow, compared to normal
vasculature in the contralateral control (B) indicated by arrow.
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Fundus Examination

Pathologic changes in retinal structure were evident in the Sprague Dawley group.
Within 30 weeks after surgery, there was a greater than 35% increase in optic cup area of
the hypertensive eye compared with contralateral normal eye. There was also a 14%
increase in cup to disc ratios as measured by both width and height. The cup to disc
ratios for both width and height increased to 0.65±0.045 and 0.66±0.045, respectively in
the operated eye when compared to 0.57±0.07 width and 0.58 ±0.06 height in the control
eye (p<0.05). The optic disc of the operated eye remained circular determined by a
width to height disc diameter ratio of 1.01. A decrease in retinal vasculature was also
apparent. A significant correlation was noted between IOP and cup to disk ratios for
width (r2 = 0.908,/? < 0.05) and height (r2 = 0.901,/? < 0.05). By comparison, fundus
examination of the contralateral eye was normal. The optic disc was circular as
determined by the width to height disc diameter ratio of 1.01. There was no substantial
cupping.

Corresponding changes were not observed in the Long Evans or Wistar rats where
the duration of increased IOP was less than six weeks. Due to their pigmentation, the
optic disc margin was not easily demarcated in Brown Norway rats. However, 14 weeks
after surgery, the morphology of optic disc and retinal vessels had not changed from their
presurgical appearance.
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Response to timolol

To ascertain if the operated eyes respond to standard antihypertensive therapy, a
single dose (20 |il) of timolol 0.5% was administered to the hypertensive eye. IOP was
measured every 30 minutes over a 2 hr period (Figure 11). Within 0.5 hr, in Sprague
Dawley rats timolol significantly decreased IOP from baseline and it remained
significantly decreased for over 2 hr (p<0.05). Timolol decreased the IOP to the extent
that it was no longer different than that of the contralateral eye (p= 0.77). In Brown
Norway rats IOP initially decreased from pretreatment values (p<0.05), but the IOP
remained greater than that in the contralateral eye (p < 0.01). Long Evans rats had the
least response to timolol treatment. At 0.5 hr, there was only a 2 mmHg difference
between eyes, and IOP remained significantly higher than in the contralateral eye (p <
0.01). No drug crossover IOP effects were observed in contralateral eyes of any strain
throughout the study period.

Discussion

As new pharmacologic approaches for treatment of glaucoma emerge,
demonstration of efficacy and comparison with current therapy requires suitable
preclinical models. Although the specific etiology of primary glaucoma is not well
understood, increased resistance to aqueous humor outflow from the eye causes IOP to
increase. As ocular hypertension remains a primary risk factor, most models use an
increase in IOP as their primary end point.
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Figure 11: Effects of timolol (0.5%, 20ul) on IOP were measured over a 2 hr period in
three rat strains with surgically elevated IOP.
Sprague Dawley rats responded rapidly with a significant decrease at 0.5 hr and lasting 2
hr (p<0.05). The response of Brown Norway rats was moderate with a significant
decrease only at 0.5 hr and 1 hr (p<0.05). Long Evans rats had small but not significant
decrease in IOP. All data are mean ± SD (n=4/group), all comparisons conducted by
ANOVA analysis. Data at 0 hr represent baseline values before administration of timolol.
* Significant compared to baseline, p<0.05

Both surgical and nonsurgical approaches have focused on increasing resistance to
aqueous humor outflow. When hyaluronic acid was injected intracamerally in Wistar rats,
IOP increased, but only for 8 days; multiple injections were required to sustain the
increase m . Karim et al elevated IOP by argon irradiation of rat trabecular meshwork in
Wistar rats 120 . Also, Levkovitch-Verbin et al used a diode laser aimed at the trabecular
117

meshwork and vortex veins which raised IOP in Wistar rats for 9 weeks

With only moderate success of the nonsurgical approaches to sustain ocular
hypertension, surgical intervention has been more successful. After cauterization of 3
vortex veins and 2 episcleral veins in Brown Norway rats, only 36% developed elevated
*

IOP with duration of 5 weeks

10A

. Cauterization of 3 episcleral veins increased IOP 1.6

fold over control in Wistar rats, but required re-cauterization after 6 months 122. In our
study, compared to cauterization, minimally invasive vortex vein ligation resulted in
significant IOP elevation that lasted at least a year. In addition, the success rate for
developing elevated IOP was higher (-90% for Sprague Dawley rats). Therefore,
ligature of the vortex veins yields in a consistent and longer lasting ocular hypertension.
The development of our surgical technique to achieve a sustained elevation of
IOP required several iterations. Unfortunately, complete dissection to expose the vortex
vessels caused anterior segment ischemia manifested as erythema, corneal opacification
and central ulceration that did not improve with tarsorrhaphy and antibiotics. Ocular
hypotension frequently occurred, probably due to disruption of perfusion to the iris
major arterial circle, as well as aqueous humor production by the ciliary body. This
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response is analogous with the anterior segment ischemia that occurs in patients after
strabismus surgery when multiple rectus muscles are disinserted.

These unsatisfactory surgical results prompted us to develop a technique, in which
careful attention was given to minimizing surgical trauma, primarily by identifying the
vortex vessels directly through the conjunctiva and then ligating them using only very
small minimal incisions. We hypothesized that the greater the surgical insult, the faster
and more extensive the development of collateral circulation. It was crucial that incisions
of the conjunctiva be limited to the immediate area of the vortex veins. Ligation rather
than cautery of vortex veins is essential. Collateral circulation was more extensive when
cautery alone or cautery following ligation was used. It is possible that the use of cautery
alone is a sufficient local insult to stimulate the formation of collaterals. Similarly, in
other studies where only cautery was used, the duration of ocular hypertension was
shorter than that following vortex vein ligation

'.

Following ligation of three of the four vortex veins, a steady elevation was
achieved without negative impact on other ocular structures except for the retina. All
possible ligation combinations were attempted, but superior (nasal and temporal) and
inferior temporal vessels were most commonly ligated due to their ease of access. The
inferior nasal vein was most difficult to access and caused excessive damage to
surrounding tissues during ligation. Ligation of all four vortex veins resulted in infarcted
blood vessels due to almost complete occlusion of the outflow facility. Excessive
occlusion of the outflow apparatus and stimulation of angiogenic factors promotes
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formation of anastomoses or collateral circulation 127'128. This stimulus is amplified by
surgical trauma; in our study the surgical trauma was limited to the immediate area of the
vortex veins to preserve much of the normal anatomy of the eye. These novel
modifications in the surgical procedure improved the performance of the ocular
hypertension model. Using a similar technique, Yu et al reported an IOP elevation of
approximately 9 mmHg in Wistar rats over the control eye that was compromised by
collateral formation in 60% of the cases 126. Subsequently, repeated ligations were
necessary to maintain the IOP elevation reported to be maintained over a 7 month period.

Although the increase in IOP was of similar magnitude in Long Evans and Brown
Norway rats, these strains are less suitable models than the Sprague Dawley rats. In both
Long Evans and Brown Norway rats, the elevated IOP was not sustained and optic nerve
damage minimal. Rapid formation of anastomoses and postoperative complications
further compromised the Long Evans rat model. The Long Evans rats did not respond to
timolol and the response in the Brown Norway rats was small and of short duration. In
both strains morbidity associated with sedation was high. If increased IOP could be
sustained, Brown Norway rats have potential as a model due to the ease of observing
changes in retinal and optic nerve morphology. Preliminary studies with Wistar rats were
similarly unproductive. Wide variations in vortex vein anatomy and sedation-related
morbidity precluded inclusion of a suitable number of animals.

It was not surprising that the responses varied between the rat strains because
there are considerable differences in the biochemical, pharmacological and neuronal
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responses among rat strains

'

. Although rats in these experiments were sex and age

matched, certain differences, such as response to anesthesia and surgery, persisted. Strain
dependent neovascularization and development of collateral circulation could be
attributed to innate regulators of vascularization. Compared to Sprague Dawley rats,
retinal ischemia in Brown Norway rats produces substantially more VEGF

. Nitric

oxide synthetase and glutamate activity is strain dependent, which may have important
implications for the extent of glaucomatous retinal damage developed in different strains
132

. Brown Norway rats also have impaired autoregulation of blood pressure compared to

Long Evans or Sprague Dawley rats, which may explain their poor response to beta1 33

adrenergic blockade

. If blood pressure in Brown Norway rats does not respond

normally, regulation of IOP may also be atypical, since diurnal variation in IOP
correlates directly with diurnal variations in blood pressure 134.
Additionally, this technique was also performed on New Zealand White rabbits
(data not shown). Ligation of three vortex veins failed to elevate IOP, while ligation of
all four caused excessive IOP elevation and rupture of veins. In ligated rabbits (three
vein), development of significant collateral circulation was noted (Figure 12) which could
contribute to lack of IOP elevation. Therefore, it can be concluded that this strain of
rabbits is not suited for this technique as they have a greater potential to develop
collateral circulation.
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Figure 12: Vortex vein ligation surgery performed on New Zealand White Rabbits.
No IOP elevation was produced in the operated eyes due to significant collateral vessel
formation within 2 weeks of surgery.
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Once the effectiveness in maintaining ocular hypertension was established, we
examined whether this model mimicked other salient factors associated with glaucoma.
In our model significant loss of both a- and b- wave amplitudes were noted 32 weeks
after surgery. The loss of retinal ganglionic cells and diminished amplitude of ERG wave
SO

pattern is synonymous with glaucomatous damage

. While a-wave changes are

pathognomic, the decrease in b-wave amplitudes raise concerns of possible ischemic
involvement and choroidal hypertension in the ensuing retinal damage. With any
occlusive surgical procedure, a potential for ischemic damage exists. With vortex vein
ligation, dilation of choroidal vessels leads to IOP elevation that is gradual and prolonged
and does not directly affect central vessels of the eye. Therefore any resulting ischemic
insult is not as severe in comparison to damage induced by ligature of optic vessels
B-wave deficits are also observed in DBA/2NNia mice model of angle closure glaucoma
136

. In this genetic model both a- and b-wave amplitudes decreased after 8 months, thus

sharing many similarities with human glaucoma, however the specific causes of the ERG
changes in DBA/2NNia mice is not clear. Following other procedures, such as injection
of ICG dye in the anterior chamber with a rapid onset of ocular hypertension, it would be
expected that ischemic injury would be a major contributor to retinal damage. In these
models, b-wave damage is prominent in comparison to the inner retinal function

124

. In

all cases, the glaucomatous condition presents with both a- and b-wave deficits and
contributions by ischemia and choroidal hypertension cannot be ruled out. In addition to
the significant retinal functional damage, pathologic structural changes were observed in
retinal vasculature and the optic disc. Although all measured parameters (area, height
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and width) of the cup and disc increased in the operated eye, the disc remained circular,
indicative of early glaucomatous changes.

The results of the present study help to define optimal conditions to create an
effective rat ocular hypertensive model. While IOP increased gradually in most strains,
only in Sprague Dawley rats was it sustained for up to a year. Retinal degeneration was
coincident with the sustained increase in IOP. The Sprague Dawley rat model was also
remarkably free of postoperative complications and responded well to standard
pharmacotherapy with timolol. Indeed, we have recently used this Sprague Dawley
model to demonstrate that repeated topical administration of the cannabinoid agonist
WIN-55-212-2 significantly decreased IOP without developing tolerance 90. In
conclusion, the results of the present study indicate that ligation of three of four vortex
veins in the Sprague Dawley rat is an optimal preclinical rat model to investigate
pharmacological treatments for intraocular hypertension.
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CHAPTER VI

OCULAR PHARMACOKINETICS OF 0-1812 AND 0-2545 IN AN
ARTIFICIALLY PERFUSED RAT EYE

Introduction

A major interest in ocular pharmacology has been the description and
improvement of therapeutic drug absorption in the compartments of the eye. One of the
primary factors affecting a drug's pharmacokinetic profile is its lipophilicity. It is well
known that lipophilic compounds can more easily cross biologic membranes, and thus,
can more easily reach their sites of action. Cannabinoids are inherently lipophilic,
especially 0-1812. Lipophilic compounds are difficult to solubilize and to dissolve
frequently require solvents like ethanol and DMSO. Moreover, lipophilic compounds
tend to precipitate out of solution and have a limited shelf life.

While hydrophilic compounds would be safer to administer, their absorption
profiles must be comparable to that of lipophilic compounds. Measurements of
intraocular drug concentrations over time are limited, however, by the amount of aqueous
or vitreous samples that can be obtained.

A relatively new method for the elucidation of pharmacokinetic profiles in vivo is
microdialysis. It has been successfully utilized for regional sampling of low-volume
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compartments of many tissues, such as the brain, joints, kidney, and eye

. By taking a

minute amount of aqueous humor and re-perfusing an equivalent volume, microdialysis
sampling allows for serial measurements of the aqueous fluid in order to create a
complete concentration versus time curve for an individual subject. Rittenhouse et al
used microdialysis sampling to produce intra- and inter-animal absorption profiles of
propranolol after topical and intracameral injection, showing it to be an accurate and
easily reproducible method

. In this study, we will use a similar method to examine the

pharmacokinetics of lipophilic and hydrophilic O-compounds after topical ocular
administration.

Experimental Design

Animal Model
Male rats weighing ~ 200 gm (14 Sprague Dawley, 4 brown Norway, 59 Long
Evans and 5 Wistar) underwent vortex vein ligation. All studies were conducted in
accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision
Research, and were approved by the Eastern Virginia Medical School (EVMS)
Institutional Animal Care and Use Committees.

Surgical Model
An adult male Sprague Dawley (SD) rat was euthanized by IP injection of Fatal
Plus in accordance with IACUC (Institutional Animal Care and Use Committee)
regulations. Placed in supine position, Y incision was made to expose chest cavity. Once
descending aorta was exposed and isolated, the inferior aorta was sutured closed,
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superiorly to the suture but inferior to the aortic arch. A window into the lumen of the
aorta was made and tubing placed securely inside; held with a suture and surgical glue.
At the end proximal to the heart, the ascending aorta was sutured closed. Once a closed
system was achieved, profusion began and maintained IOP during cannulation without
elevation of IOP. Modified 27 gauge needle accompanied by the cannulation apparatus
was inserted into the OS anterior chamber. OD received the same insertion technique
using the 27 gauge needle into the OD vitreous chamber. Perfusion with IX PBS was
maintained for a period with stability, topical drug was added and samples taken every 10
minutes for 2 hours for analysis by HPLC.

Cannabinoid concentration was quantified by HPLC. Using a modification of the
method described by Barberi-Heyob and colleagues, dialyzed aliquots were injected on a
5-um reverse-phase column (Prodigy 5 um ODS(2) analytical column, 150 x 4.6 mm,
Phenomenex, Torrance, CA) at ambient temperature with a mobile phase of acidified
acetonitrile water (pH = 4.0) solution94'95. The flow rate was 1 mL/min with UV
detection (254 nm). Chromatograms were analyzed using Beckman System Gold
software (Beckman Instruments, Inc., Fullerton, CA).
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Figure 13: Pharmacokinetic profile of 0-1812 and 0-2545 in the anterior chamber of an
artificially perfused rat eye.
Eyes were dialyzed for 120 min with a sample taken every 10 min.
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Results
Lipid soluble 0-1812 more effectively penetrates the anterior chamber

Cannabinoid concentration as a result of topical administration was assessed in
the anterior chamber of a rat eye (Figure 13). After artificial perfusion, dialysates were
collected every 10 min and analyzed with an HPLC. Both 0-1812 and 0-2545 rapidly
crossed through the cornea into the anterior chamber of the eye. Lipid soluble 0-1812
was more effective than water soluble 0-2545 in penetrating the anterior chamber, a
difference of 2 nM was noted (n=l for each drug). Cannabinoid concentration decreased
over time. After 80 min, there was no trace of 0-2545; however 0-1812 concentration
was greater than 2 nM for 120 min.

Lipid soluble Q-1812 more effectively penetrates the posterior chamber

Cannabinoid concentration after topical administration was assessed in the
posterior chamber of a rat eye (figure 14). Cannabinoid transport to the posterior
chamber was not as rapid as compared to the anterior chamber. Concentration of 0-1812
in the posterior chamber was 5 nM after 30 min and decreased to 2 nM after 90 min
where it remained for the duration of the study (120 min). In contrast, maximal
concentration of 0-2545 was 3 nM after 30 min, but was eliminated after 80 min. After a

single topical dose of 0-1812 or 0-2545, lipid soluble 0-1812 more effectively
penetrated the posterior chamber than water soluble 0-2545.
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Figure 14: Pharmacokinetic profile of 0-1812 and 0-2545 in the posterior chamber of
an artificially perfused rat eye.
Eyes were dialyzed for 120 min with a sample taken every 10 min.
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Discussion

Compared to other tissues, the aqueous and vitreous chambers are relatively
privileged sites. Compared with systemic administration, where drug plasma
concentration is often sufficient to obtain therapeutic levels in a given region, it is
difficult to do so in the eye because certain drugs do not cross the blood-vitreous barrier
137

. However, certain substances are more suited than others to cross the blood-vitreous

barrier, namely, lipophilic compounds. Mayers et al compared the intraocular
concentrations of lipophilic chloramphenicol versus hydrophilic amikacin after
intravenous administration

. They demonstrated that chloramphenicol reached higher

concentrations in the anterior chamber than did amikacin. Moreover, chloramphenicol
had a rate of elimination from the aqueous humor identical to its rate of elimination from
the serum, while amikacin had a lower peak aqueous concentration and was more quickly
eliminated.

Lipophilic drugs can reach therapeutic levels in the eye when administered
intravenously, although high doses are required. Mayers et al found that, when directly
injected into the eye, chloramphenicol and amikacin were both eliminated more quickly,
and the two compounds had comparable half-lives

138

. They attributed this to the lack of

a membranous barrier to the drainage mechanism of Schlemm's canal, which abolishes
the lipophilic compound's absorptive advantage. While intravitreal injection might hold
promise for improved concentration curves of hydrophilic compounds, it is not a
clinically desirable option due to patient discomfort, anxiety, and increased risk of
infection.
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The ideal mode of administration of ocular medication is topically. Drops can be
applied easily by the patient in almost any setting. Studies have shown, however, that
topically-administered drugs achieve much lower concentrations than those injected
intraocularly93. To evaluate how the concentrations of these drugs affect their action, an
accurate description must be made of its pharmacokinetic profile. This can be done in a
number of ways. One method is to take serial samples of aqueous humor from the same
subject. The volume of fluid available for sampling is limited, however. While this
might be overcome by a "washout" period in between treatments to replenish aqueous
fluid and clear the experimental compound, repeated cannulation of the sclera could lead
to inflammation and scar tissue formation, which would affect sampling. Another
technique involves taking samples of fluid from a large number of subjects at staggered
time intervals after administration of the experimental compound and combining all the
data into one concentration vs. time curve. This can be skewed by variability between
individual subjects, however.

Several methods have been employed to accurately model concentration curves in
the eye. Drusano et al attempted to create a reliable curve of plasma concentrations vs.
vitreous concentrations of ciprofloxacin using single measurements of intraocular
concentrations from multiple subjects and a population pharmacokinetic modeling
program 137. While this allows for fewer vitreous samplings, repeated plasma samplings
are required; furthermore, it is based on data compiled from different subjects which may
be skewed by inter-subject variation. Mayers et al utilized a method consisting of
multiple paracenteses to observe the absorption of antibiotics

138

. By beginning to sample
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from different subjects at different time intervals, they showed that the number of
samples taken do not affect clearance of the drug from the aqueous humor. This method
required many subjects, however, and did not rule out the possibility of an occult
inflammatory process affecting the clearance of the antibiotics.

Using in vivo microdialysis, a pharmacokinetics of lipid and water soluble
cannabinoids can be made with continuous sampling. Since these cannabinoids are
newly synthesized, their pharmacokinetic profiles have not been elucidated. After a
single topical administration, lipid-soluble 0-1812 effectively penetrated both the
anterior and posterior chamber and was maintained for at least 120 min. 0-2545, being
water-soluble, did penetrate both the ocular chambers, but was eliminated more rapidly
than the lipid soluble 0-1812.
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CHAPTER VII

TOPICAL APPLICATIONS OF NOVEL CANNABINOIDS, 0-1812
AND 0-2545, REDUCED INTRAOCULAR PRESSURE IN A RAT
OCULAR HYPERTENSIVE MODEL

Introduction

IOP is the most important risk factor for the development of glaucoma, a leading
cause of blindness world wide 21 ' 139 ' 140 . Consequently, the reduction of IOP is recognized
as the main treatment to reduce visual loss in glaucoma patients. Several multicenter
clinical trials have demonstrated that reducing IOP retards the progressive visual field
damage in patients with primary open angle glaucoma or normal tension glaucoma *'36.

A variety of naturally occurring and synthetic cannabinoid agonists have been
evaluated for their ability to reduce IOP in humans and laboratory animals 14M43 . Most
bind both cannabinoid receptors, the CB1 receptors which are predominantly localized in
the CNS 63 and the CB2 receptors identified in the periphery and associated with immune
function

144

. It has been suggested that the IOP reducing effects of cannabinoid agonists

are related to their actions on the CB1 receptor, whose presence has been demonstrated in
the ciliary body, iris, trabecular meshwork, and retina 13'16>44,52. Stimulation of these CB1
receptors is hypothesized to decrease IOP and, consequently, may retard the progression
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of glaucoma. Recently, CB2 receptors in the trabecular meshwork have also been
c-i

implicated in cannabinoid-mediated IOP reduction .

The therapeutic usefulness of systemic cannabinoids is limited by their welldescribed psychomimetic and systemic effects; however, topical drug delivery may
reduce these problems. The primary purpose of the present study is to determine whether
acute topical administration of 0-1812, 0-2545 is comparable to WIN 55212-2, a well
studied high efficacy aminoalkylindole cannabinoid analog. With topical application,
undesired systemic and ocular effects can be obviated while maintaining efficacy. The
efficacy of 0-1812, 0-2545, and WIN 55212-2 was evaluated in rats with high IOP,
following surgical occlusion of three vortex veins. As an additional measure, receptor
(CB1 or CB2) dependency of the IOP effect in a rat chronic ocular hypertensive model
was studied by using selective antagonists, SR 141716A or SR 144528, for each
respective cannabinoid receptor.

Experimental Design

Sprague Dawley rats were randomly assigned to either 0-1812, 0-2545, WIN
55212-2, or Tocrisolve™ (vehicle) treatment groups. Only 0-1812 and WIN 55212-2
were dissolved in Tocrisolve™ while 0-2545 was water soluble and dissolved in PBS.
These compounds were applied topically to the hypertensive right eye. The vehicle
served as the negative control while WIN 55212-2 was a positive control. All animals
were allowed a minimum washout period of 1 wk between subsequent experiments. The
left eye (OS) served as the untreated control. At the beginning of each experiment,
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baseline IOP, heart rate (HR), and blood pressure (BP) measurements were obtained. IOP
measurements were repeated at 30, 60 and 120 min after drug administration, in the
treated eye (OD), as well as in the contralateral untreated eye (OS). HR and BP were
also measured at 30, 60 and 120 min after drug administration. Before and at the
conclusion of each experiment, all eyes were examined by slit lamp for signs of ocular
irritation and by in vivo confocal microscopy for changes in corneal thickness.

Experiments using CB1 antagonist, SR141716, or CB2 antagonist, SR 144528,
were performed to determine receptor specificity of these compounds. The CB
antagonists were prepared by dissolving 50 ug of compound in 50 ul of Tocrisolve™
(0.1%). To get maximal effect, the antagonists were applied topically 30 min prior to the
administration of the cannabinoids. The CB1 antagonist was SR141716 (Ki [CB1] = 5.6
nM, Ki [CB2] >1000 nM) I 4 5 and the CB2 antagonist was SR 144528 (Ki [CB2] = 0.6
nM,Ki[CBl] = 437nM) 146 .

Additional experiments to test for the confounding effects of sedation on IOP
were performed. In this experiment, animals were sedated (ketamine 40 mg/kg and
acepromazine 6 mg/kg) and IOP measured at 0, 30, 60 and 120 min in both operated and
contralateral control eye.
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Figure 15: Dose response to topically applied 0-1812 in surgically hypertensive eyes.
The baseline IOP (t=0) was 16.0 ±0.9 mmHg. N = 10 rats/group.
* Significantly reduced when compared to baseline,/? < 0.05.
f Significantly reduced when compared to vehicle, p<0.05.

86
Results
Effects of topically applied 0-1812

At baseline (t=0), the IOP for the operated eye (OD) was 16.0 ±0.9 mm Hg and
for the contralateral (non-operated) eye was 10.1 ± 0.5 mm Hg. Following a single
topical application of 0-1812 (1.0, 0.1 and 0.01%) or vehicle alone to the operated eye,
the change in IOP (mm Hg) from baseline was measured for up to 120 min (Figure 15).

After 30 min, all concentrations of 0-1812 significantly decreased IOP (p
<0.001) from 30 to 120 min. Maximal effect was observed at 60 min for all
concentrations. At this time period, 1.0 % elicited a significantly greater IOP reduction
than either 0.1 or 0.01% concentrations (p<0.001). At the end of the study period (120
min), only 1.0% and 0.1% treatment continued to maintain IOP reduction while for the
0.01% concentration IOP had already returned to baseline. Thus, magnitude and duration
of effect was dose dependent. Tocrisolve™ (vehicle) alone had no effect on IOP
(p>0.08). No crossover effects were seen in the contralateral eyes.
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Figure 16: Dose response to topically applied 0-2545 in surgically hypertensive eyes.
The baseline IOP (t=0) was 16.0 ±0.9 mniHg. N = 7 rats/group.
* Significantly reduced when compared to baseline,/? < 0.05.
f Significantly reduced when compared to vehicle, p<0.05.
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Effects of topically applied 0-2545

At baseline (t=0), the IOP for the operated eye (OD) was 16.0 ±0.9 mm Hg and
for the contralateral (non-operated) eye was 10.1 ± 0.5 mm Hg. Following a single
topical application of 0-2545 (1.0 and 0.1%) or vehicle alone to the operated eye, the
change in IOP (mm Hg) from baseline was measured for up to 120 min (Figure 16).

After 30 min, both concentrations of 0-2545 significantly decreased IOP (p
<0.03, n=7) for up to 120 min. Maximal effect on IOP was observed 60 min after
administration of 0-2545. The IOP reduction was similar for both 1.0 and 0.1%
concentrations throughout the study period. At the end of the study period (120 min),
although IOP remained significantly reduced from baseline, both 1.0 and 0.1% treatments
had already started to return toward baseline (p < 0.05, n=7). There was no effect of
vehicle (PBS) on IOP as well as no effect in contralateral eye.
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Figure 17: Topically applied WIN55212-2 in surgically hypertensive eyes.
The baseline IOP (t=0) was 16.0 ±0.9 mmHg. N = 10 rats/group.
* Significantly reduced when compared to baseline,/? < 0.05.

90
Effects of topically applied WIN55212-2

At baseline (t=0), the IOP for the operated eye (OD) was 16.0 ±0.9 mm Hg and
for the contralateral (non-operated) eye was 10.1 ± 0.5 mm Hg. Following a single
topical application of WIN55212-2 (1.0, 0.25, 0.06, and 0.015%) or vehicle alone to the
operated eye, the change in IOP (mm Hg) from baseline was measured for up to 120 min
(Figure 17).

By 30 min, all concentrations of WIN55212-2 significantly decreased IOP (p
<0.001) from 30 to 120 min, except for WIN55212-2 0.015% (p = 0.59, n=10).
WIN55212-2 1.0, 0.25 and 0.06% also significantly reduced IOP compared to 0.015%
concentration 30 min after administration (p=0.03). Maximal effect on IOP was observed
60 min after administration of WIN55212-2. At this time period, both 1.0 and 0.25%
elicited a significantly greater IOP reduction than 0.06 and 0.015% concentrations
(p<0.001). At the end of the study period (120 min), only 1.0% treatment continued to
maintain IOP reduction while 0.25 and 0.06% concentrations had already started to return
toward baseline. The magnitude and duration of effect was dose dependent. Vehicle
alone had no significant effect on IOP (p>0.08).
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Figure 18: Topical administration of WIN55212-2 in the operated eye significantly
reduced IOP, but had no effect in the contralateral eye.
Data presented as mean ± SEM.
* Significantly reduced when compared to baseline (t=0),p <0.001, n=10.
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Effect on contralateral eye

IOP changes in the contralateral control eye (OS) were recorded after treatment
with WIN 55212-2, 0-1812, 0-2545 or vehicle. There was no apparent cross over effect
in the contralateral control eye even at the highest concentration of WIN55212-2 1.0%
(Figure 18). For example, IOP was reduced from 16.2 ±0.9 mmHg at baseline (t=0) to
9.0 ±0.5 mm Hg after 60 min in the treated eye. There was no concomitant change in the
untreated eye (p - 0.59); i.e. IOP was 10.1 ± 0.5 mmHg at baseline and 10.4 + 0.4 mmHg
after 60 min (n=10). Also, after treatment with 0-1812 or 0-2545, IOP in the
contralateral eye was unaffected (see Figure 15 and 16). Sedation, itself, did not
significantly alter IOP in the hypertensive eye.

Effect of CB1 receptor antagonism on Q-1812 or Q-2545

Topical application of 0-1812 1.0% alone reduced IOP by 26 % after 30 min and
38 % by 120 min (Figure 1). After pretreatment with CB1 antagonist, SR141716 (2mM),
topical treatment with 0-1812 had no effect on IOP at 30, 60 and 120 min, indicating
significant antagonism of 0-1812 by SR141716 (Figure 19).

When administered alone, 0-2545 1.0% reduced IOP by 18 % after 30 min and
23 % by 120 min (Figure 2). Pretreatment with CB1 antagonist, SR141716 (2mM), did
not reduce IOP within 30 min. However, a slight reduction of 9 ± 0.4% in IOP was
observed 60 min after instillation of 0-2545, which recovered to baseline value after 120
min. Topical administration of SR141716 (2mM to 0.02mM) alone had no effect on IOP
(data not shown). No crossover effects were seen in the contralateral eye.
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Figure 19: Effect on IOP of CB1 antagonist, SR141716, followed by 0-1812 or 0-2545.
CB1 antagonist (2mM), SR141716, was applied topically 30 min (see arrow) prior to
administration of each cannabinoid (t = 0 min). Data presented as mean ± SEM. N=6.
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Figure 20: Effect on IOP of CB1 antagonist, SR141716, followed by WIN55212-2.
CB1 antagonist, SR141716, was applied topically 30 min (see arrow) prior to
administration of WIN55212-2 (t = 0 min). Data presented as mean ± SEM.
* Significantly reduced from baseline (t=0),p<0.05.
t Significantly greater than 1.0% WIN55212-2 alone treatment, p<0.05.
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Effect of CB1 receptor antagonism on WIN 55212-2

Topical application of WIN55212-2 1.0% alone reduced IOP by 32 % after 30
min and 52% by 120 min (Figure 17). After pretreatment with CB1 antagonist,
SR141716 (2mM), the maximal reduction of only 8.0±2.1% occurred at 30 min (n=3).
This reduction was significantly less than WIN55212-2 alone (p=0.009), but significantly
lower than baseline (p=0.03, n=3, Figure 20). IOP recovered to baseline within 120 min
indicating significant antagonism of WIN55212-2 (p<0.001, compared to WIN55212-2
alone, n=3).

The effect of SR141716 on the response to WIN55212-2 was concentration
dependent. After decreasing the concentration of SR141716 50 fold (0.04 mM),
WIN55212-2 decreased IOP by 20% at 30 min and by 10% at 120 min (p=0.15, and
p<0.001 respectively when compared to WIN55212-2 alone;p=0.02 andp=0.05
respectively when compared to baseline, n=3). After a 100 fold decrease (0.02 mM),
WIN55212-2 maximally reduced IOP by 23% at 30 min and by 14% at 120 min (p=0.29,
andp=0.04 respectively when compared to WIN55212-2 a\one;p=0.02 andp=0.06
respectively when compared to baseline, n=3).
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Figure 21: Effect of CB2 antagonist, SR 144528, followed by 0-1812 or 0-2545 on IOP
was tested for 120 min.
CB2 antagonist was applied topically 30 min prior to administration of each cannabinoid.
Data presented as mean ± SEM.
* Significantly reduced from baseline (t=0),p<0.05.

Effect of CB2 receptor antagonism on 0-1812 or 0-2545

Effects of pretreatment with CB2 antagonist, SR144528 (2mM), on IOP were
studied after topical administration of 0-1812 1.0%, or 0-2545 1.0% (Figure 21, n=3).
After pretreatment with SR144528, 0-1812 1.0% reduced IOP by 11 ± 0.6% at 30 min
(p<0.0001 when compared to 0-1812 alone;p=0.05 when compared to baseline, n=3)
and by 13 ± 1.3% mmHg after 120 min (p=0.009 when compared to 0-1812 alone;
p=0.05 when compared to baseline, n=3).

In the presence of SR144528, the IOP response to 0-2545 1.0 % was decreased
by 26 ± 0.4 % after 30 min (p=0.15 when compared to 0-2545 alone; p=0.03 when
compared to baseline, n=3) and by 28 ± 0.9% after 120 min (p=0.005 when compared to
0-2545 alone; p<0.0001 when compared to baseline, n=3). Topical administration of
SRI44528 (2mM to 0.02mM) alone did not have any effect on IOP (data not shown).
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Figure 22: Inhibition of WIN55212-2 by the CB2 antagonist, SR 144528.
CB2 antagonist was applied topically 30 min prior to administration of WIN55212-2.
Data presented as mean ± SEM.
* Significantly different from baseline (t=0),p<0.05.
f Significantly different from WIN55212-2 1.0% alone treatment, p<0.05.

Effect of CB2 receptor antagonism on WIN 55212-2

Pretreatment with CB2 antagonist, SR144528 (0.02mM) did not significantly
inhibit the effects of WIN55212-2 1.0% (Figure 22, n=3). Following SR144528
pretreatment, IOP was reduced from a baseline of 19.5±0.4 mmHg to 9.0±0.4 mmHg at
30 min (p= 0.13 when compared to WIN55212-2 alone;p= 0.05 when compared to
baseline, n=3) and 9.0±0.1 mmHg at 120 min (p=0.18 when compared to WIN55212-2
alone; p-0.03 when compared to baseline, n=3).

When pretreated with higher doses of SR144528 (0.04mM or 2mM), the
hypotensive effects of WIN55212-2 1.0% diminished. After doubling the concentration
(0.04 mM), WIN55212-2 decreased IOP by 30% at 30 min and by 25% at 120 min
(p=0.80, andp= 0.01 respectively when compared to WIN55212-2 alone;p=0.02 and
p=0.05 respectively when compared to baseline, n=3). A further SR144528 increase (to
2mM), blocked the WIN55212-2 mediated IOP effect (for 30 and 120 min,p=0.003 and
p=0.001 respectively when compared to WIN55212-2 alone;/?=0.11 andp=0.17
respectively when compared to baseline, n=3).

Effects of WIN55212-2 on heart rate and blood pressure

Even at the highest concentration tested 0-1812, 0-2545 or WIN55212-2 (1.0%)
had no effect on heart rate or blood pressure. Although, after administration of WIN
55212-2, heart rate apparently changed from 434 ±12 bpm at baseline to 414 ±10 bpm at
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120 min, this change was not significant (p=0.70). Likewise, neither systolic nor
diastolic blood pressure changed significantly (p=1.00,p=0.67, respectively compared to
baseline).

Examination for ocular irritation

Slit lamp examination conducted at the end of each experiment revealed no signs
of ocular toxicity attributable to vehicle, 0-1812, 0-2545, WIN55212-2, SR141716, or
SR144528. No signs of inflammation, conjunctival chemosis/swelling, conjunctival
discharge, aqueous fibrin/flare, loss of the pupillary light reflex, obscuration of iris
structures, or corneal opacity were observed. In all treatment groups mild central corneal
staining was noted consistently. However, similar corneal staining also occurred in the
untreated control eyes. This finding was most likely a result of repeated applanation with
the Goldmann tonometer rather than a drug- or vehicle-induced effect.

Corneal thickness

Confocal examinations of the cornea were performed at conclusion of each
experiment. Treatment with 0-1812, 0-2545 or WIN 55212-2 did not change central
corneal thickness as it remained at a baseline thickness of 320±25 um.
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Discussion
It has been over a decade since a new class of pharmacologic agents was
introduced for the clinical management of glaucoma25. Currently available therapeutic
approaches for the treatment of glaucoma include prostaglandin analogs, beta-adrenergic
blockers, alpha-2 adrenergic agonists, carbonic anhydrase inhibitors and cholinergic
agonists. Each of these has a well known profile of clinical response and adverse effects.
Up to 50% of patients cannot be maintained on single drug therapy; most require use of
two or even three drugs to control their IOP . Even the first line agent for the treatment
of glaucoma, timolol, as monotherapy controlled IOP in only 98 of 155 patients (63.2%)
34

. More recently, in the Ocular Hypertension Treatment Study, 40% of patients

randomized to treatment required more than one medication to achieve the 20% reduction
goal 35 .

For over thirty years cannabinoids have been touted for their potential to decrease
IOP 6. However, cardiovascular and psychotropic effects complicate systemic
administration

' . Numerous studies showed that systemic administration of

cannabinoids produced an unwanted reduction in systolic and diastolic blood pressure,
decreased heart rate and variable changes in pupil diameter 42~44. Moreover, the
associated psychotropic effects of these agents are well documented 45.

Topical administration of cannabinoids offers the theoretical advantage of
providing desirable local ocular effects with minimal, if any, systemic side-effects.
However, poor cannabinoid solubility has hindered preparation of a suitable topical
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dosage form, resulting in an inadequate effect on IOP 142'147. Vehicles with potential for
dissolving lipophilic cannabinoids include sesame oil I48 ' 149 , mineral oil 148 ' 15°,
polyethylene glycol 141'142, Tween 80 I48, and submicron aqueous emulsions 151. While
these agents have the ability to dissolve the lipophilic cannabinoids, they may also permit
sufficient systemic absorption associated with undesirable systemic effects. For example,
topical application of A 9 THC in a submicron emulsion significantly reduced IOP in
rabbits, but systemic effects were also noted 151.

Tocrisolve™, a proprietary preparation, is a vehicle designed for lipophilic
compounds, such as cannabinoids and vanilloids. Tocrisolve is composed of 1:4 soya oil
and water and is emulsified with the block copolymer Pluronic F68. In the past we have
used 2-hydroxypropyl-P-cyclodextrin as a vehicle to dissolve cannabinoids. Both 2hydroxypropyl-P-cyclodextrin and Tocrisolve™ are good solvents for WIN55212-2.
However, Tocrisolve™ not only dissolves up to 2% in WIN55212-2 compared to 1% in
2-hydroxypropyl-P-cyclodextrin but also does not require ethanol to promote solubility
90

. In this study, acute application of WIN55212-2, dissolved in Tocrisolve™ and

applied topically, produced a significant reduction in IOP. Moreover, there was a notable
lack of systemic effects, e.g. heart rate and blood pressure. In a recent study, 4 weeks of
daily topical treatment of rats with WIN55212-2 in Tocrisolve™ did not cause local
ocular toxicity, i.e. ocular inflammation, conjunctival chemosis/swelling, conjunctival
discharge, aqueous flare or fibrin, diminished corneal light reflex, iris or corneal opacity,
or corneal vascularization/staining 90. This excellent tolerability profile supports the
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potential use of these cannabinoid emulsions in the management of glaucoma in humans
where long term treatment is needed.

In normotensive rabbits Song and Slowey speculated that WIN55212-2 exerts its
ocular hypotensive effect in part through activation of CB1 receptors in the eye 16.
Studies designed to identify the distribution of cannabinoid receptor mRNA and protein
in ocular tissues support this hypothesis. Using reverse transcriptase polymerase chain
reaction technology, CB1 mRNA transcripts were expressed at significant amounts in the
retina, ciliary body and iris, but CB2 mRNA transcripts were undetectable in human eyes
51

. Likewise, a similar distribution of CB1 mRNA, with an absence of CB2 mRNA, was

found in eyes from ocular normotensive rats 13. However, there is recent evidence for
CB2 receptors on trabecular meshwork cells. Stimulation of these receptors with the CB2
agonist, JWH015, increased the aqueous humor outflow, thus contributing to their ocular
hypotensive effect53.

While the mechanism is unknown, pharmacological and histological studies
support a direct role for CB receptors in ocular tissues of the human eye, including the
ciliary epithelium, trabecular meshwork, Schlemm's canal, ciliary muscle, ciliary body
vessels and retina 152. Also, Sugrue suggests that cannabinoid receptors in the retina may
convey neuroprotection to retinal ganglion cells 22. In this study, topical application of
0-1812 or 0-2545 was compared to WIN55212-2 using ocular hypertensive rats. The
effects of WIN55212-2 1.0% and 0-1812 1.0% were comparable, while 0-2545 1.0%
was not as effective. Evidence from this study also indicates that the effect of 0-1812,
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0-2545 and WIN55212-2 is mediated primarily by CB1 receptor activation, congruent
with the ability of the CB1 antagonist, SR141716, to inhibit the effects of these drugs
(1%). When pretreated with SR141716 (2mM-0.02mM), the magnitude and duration of
drug mediated hypotensive effect was severely diminished. In this study, the effect of
SR141716 was noted as early as 30 min lasting for the entire study period. Although IOP
was only measured for 2hr, Boyd and Fremming have demonstrated that when given
orally, the duration of blockade by SR141716 is upto 8 hrs

CB1 receptors are widely distributed in the eye. The local effect of cannabinoids
at these receptors may be multifocal and remains to be fully elucidated. At the level of
the ciliary body CB1 receptor-mediated control of IOP is likely due, at least partially, to
decreased aqueous humor production 13 ' 147 ' 154 ' 155 . By contrast, CB1 receptors present in
the trabecular meshwork may increase trabecular outflow

14 52 156

' '

. Either site could be

easily reached in therapeutic concentrations following topical application of CB1
agonists, as was done in the current study. Others have speculated that IOP effects could
also be non-receptor mediated 16.

The role of CB2 receptors in IOP control has not been definitively determined.
The Ki values of the CB2 antagonist (SR144528, Ki [CB2] = 0.6 nM, and Ki [CB1] =
437 nM) used in this study were determined in Chinese hamster ovary cells whose
membranes express CB2 receptors 146. The topical dose of SRI44528 used in the current
study was considerably higher (2.0mM-0.02mM) than the Ki [CB2] of 0.6 nM. Although
the data indicate a preferential contribution of CB1 to CB2 receptors in the 0-1812, O-
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2545 and WIN 55212-2 mediated IOP reduction, the differences in receptor selectivity of
SR144528 and SR141716 in vivo are much less than expected from the in vitro
experiments. This may be related to a number of factors including the amount of
antagonist delivered to the receptors or the residency of the antagonist on the receptor.

When administered topically in rabbits, the maximum concentration of timolol in
the vitreous humor was a hundred-thousandth of that in the drop 157, indicative of the type
of reduction in concentration that might be expected in our model. With a difference in
vivo Ki, the blockade of 0-1812 and WIN55212-2 observed at the higher concentrations
of SR144528 could be due to administration of this agent in concentrations greatly
exceeding its Ki [CB2] and approaching its Ki [CB1]. Thus, nonspecific binding to the
CB1 receptor may have blunted the effect of 0-1812 and WIN55212-2 in this setting.
Although CB1 receptor effects are predominant, WIN55212-2 may also exhibit mixed
agonist activity in some tissues suggesting that there may be some role for CB2 receptors
in cannabinoid-mediated IOP control.

In this study we showed that topically applied novel cannabinoids, 0-1812 and O2545, effectively decrease IOP in a rat model of ocular hypertension. This effect on IOP
was dose dependent and mediated predominantly through CB1 receptors. Equally
important was a notable lack of systemic effects or local toxicity to ocular structures.
Thus, a new class of medications, topically administered cannabinoids, to the current
armamentarium offers the clinician more alternatives in the management of glaucoma.
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CHAPTER VIII

O-COMPOUNDS CONFER NEUROPROTECTION VIA A CB1
MEDIATED PATHWAY

Introduction

The visual pathway begins at the photoreceptors. After light stimulation, a
photoisomerization reaction in the rods and cones, initiates the visual cycle generating an
electrical signal which traverses the visual pathway terminating in the visual cortex.
While the electrical activity is transmitted to the visual cortex, the photoreceptors are
replenished with trophic factors which originate from the visual cortex. Any break in the
visual pathway leads to blindness due to either degeneration of the photoreceptors by
termination of the trophic factors or the absence of electrical activity at the
1 SS

photoreceptors

In glaucoma, risk factors such as elevated IOP, can contribute to the degeneration
of photoreceptors especially the retinal ganglionic cells. It is postulated that NMDA
channels are overstimulated as a result of an injury, for example hypoxia, which results in
elevation of glutamate and subsequently intracellular Ca [2+] leading to excitotoxicity
49

'. NMDA receptors are expressed in both outer and inner retina, mostly RGC but

limited in rods and bipolar cells 159'160. However, NMDA channels and glutamate are
necessary for signal transduction especially in the bipolar cells 24 ' 161 .

6

'

Naturally occurring delta-9-THC and synthetic cannabmoids, such as WIN
55212-2, protect neural cells from excitotoxicity as demonstrated in brain tissue and also
against perinatal brain lesions 162"164. Increase in reactive oxygen species as a result of
excessive NMD A signalling can also be countered by delta-9-THC

165

. More recent

finding suggests that NMDA mediated Ca [2+] entry into cells triggers cannabinoid
signalling

I66

.

In the previous chapter the efficacy of newly synthesized O-compounds was
established. Considering that the O-compounds are derivatives of delta-9-THC, they
should also be neuroprotective. This is a pilot study to evaluate the neuroprotective
effects of 0-1812 and 0-2545 in a rat NMDA model. We also tested the receptor
specific neuroprotective effects by blocking the CB1 receptors with SR141716 and
blocking CB2 receptors with SR144258. Additionally, the specific effect of
cannabinoids on Ca (2+) influx was examined.

Experimental Design

To induce retinal damage, male Sprague Dawley rats weighing - 2 5 0 gm, 50 to
55 days old (Harlan, Indianapolis, IN) underwent intravitreal NMDA injections. To
determine the neuroprotective effects of the cannabinoids, ERG responses were
compared between NMDA only treatment and NMDA + (0-1812 or 0-2545) treatment.
After baseline ERG measurements, animals were injected with NMDA. ERG was

measured after 1 and 2 wks. For the NMD A control group, 2 ^il of lOmM NMD A was
injected into the vitreous. For cannabinoid treated groups, 20 jo.1 of either 0-1812 1.0%
or 0-2545 1.0% was administered topically (b.i.d) for 3 days prior and for 2 days after
the NMD A injection. To determine receptor specificity, 10 ul of either CB1 antagonist
(SR141716, 2 mM) or CB2 antagonist (SR144258, 2 mM) was injected intravitreally
followed 30 min later by NMD A. For these experiments, rats were also pre-treated with
0-1812 or 0-2545 for 3 days prior and for 2 days after the NMDA and CB (1 or 2)
receptor antagonist injection.

ERG measurements were made scotopically using calibrated bright flashes to
stimulate the photoreceptors. In the dark cycle, the photoreceptors are in a depolarized
state, but when stimulated the photoreceptors repolarize and generate a characteristic
wave pattern known as the a-wave. With NMDA toxicity, the photoreceptors along with
the a-wave response are greatly affected
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. It is therefore sound to focus on the a-wave

response initially to determine the extent of neuroprotection in the photoreceptors. The
contralateral normal eye served as an age matched negative control, e.g. response in a
normal, untreated eye. Differences in amplitude of the a-waves between eyes treated
with NMDA only, the positive control, and NMDA + O-compounds were calculated and
analyzed. All data is reported as a percentage of the baseline.

At the end of 2 wks, animals were sacrificed and eyes enucleated for histology.
Retinas were harvested by bisecting the eyes peri-limbally and removing the anterior
segment. The remaining posterior segment cup was flattened with 4 radial cuts after
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which the retinal layer was carefully dissected and stained with Hematoxylin and Eosin.
For positive identification of RGC, retinal flat mounts were compared with cross-sections
for cell shape, placement and distribution. Cell counts were performed by knowledgeable
masked observers. For each retina, at least 2 microscopic fields of 50 urn were captured
per quadrant at predetermined distance from the optic cup (200 um). The total retinal
area was approximately 500 urn . Retinal cell counts were averaged for each field and
comparisons made between O-compound treated, contralateral control and positive
control NMDA treated eyes. Retinal cell counts are expressed as cells per 50 urn ±SD.

Results

NMDA induced excitotoxicity is prevented by novel cannabinoids

NMDA and endocannabinoids altered retinal function (Figure 23). Damage
induced by NMDA was severe and reduced a-wave amplitude by 36±16 % (p<0.001,
n=6) from baseline in one week. Co-administration of NMDA with 0-2545 resulted in a
41±17 % (p<0.001, n=6) loss a-wave amplitude, similar to that of NMDA alone after one
week. However, only 0-1812 effectively mitigated the toxic effect of NMDA in one
week, with only a 19±13 % loss in a-wave amplitude, which while significantly less than
baseline (p<0.01, n=6), was also a significantly smaller decrease than NMDA alone
(p=0.05, n=6).
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After 2 wks, NMDA induced damaged continued to progress to 46±9 % a-wave
amplitude loss (p<0.001, n=6), but cannabinoid treatment resulted in improved retinal
function. Lipid soluble 0-1812 was the most effective endocannabinoid as a-wave
amplitude was only 7±12 % less than baseline after two weeks, which was not
significantly less than baseline (p=0.08, n=6). Water soluble 0-2545 also countered the
effects of NMDA but retinal function was significantly less than baseline (31±13 %,
p<0.05, n=6). Thus, it was not as effective as 0-1812.
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Figure 23: Topical treatment with 0-1812 or 0-2545 after intravitreal injection of
NMDA.
Retinal function was measured with electroretinography (ERG) one and two weeks after
NMDA injection. Alterations in retinal response as a result of treatments were assessed
by the a-wave amplitude and expressed as percent of baseline.
* Significantly reduced from baseline, p<0.001
| Significantly greater than NMDA alone,p<0.05
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Table 5: Retinal function was measured with electroretinography (ERG).
Alterations in retinal response as a result of treatments were assessed two weeks after
NMDA injection by quantitating a-wave amplitude. Results are expressed as percent loss
from baseline.

Two Week
NMDA
0-1812
0-2545

Drug alone
% loss ± SEM

+ SR141716
% loss ± SEM

+ SR144258
% loss ± SEM

N

46±9*
6
7±12f
45±17*
6
7±10t
32±8*f
6
34±7*fJ
31±13*tJ
* Significantly less than baseline, p<0.001
f Significantly less than NMDA alone treatment,p<0.001
% Significantly greater than 0-1812 alone treatment, p< 0.03
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Neuroprotective effect in the presence of CB1 receptor antagonist

To determine specific CB receptor involvement in neuroprotection, CB1
antagonist SR-141716 (2mM) was injected intravitreally while either 0-1812 or 0-2545
(2mM or 1.0%) was administered topically (Table 5). After two weeks, the CB1
antagonist attenuated the effects of 0-1812 as the a-wave amplitude loss was 45±17 %
which was significantly less than baseline and 0-1812 alone (p<0.001, n=6). SR-141716
did not have an effect on 0-2545 action as a-wave amplitude loss was 32±8%, similar to
that of 0-2545 alone treatment (31±13%).

Neuroprotective effect in the presence of CB2 receptor antagonist

CB2 receptor antagonist, SR-144258 (2mM), was injected intravitreally to
determine the role of CB2 receptors in neuroprotection (Table 5). Either 0-1812 or O2545 (2mM or 1.0%) was administered topically. After two weeks, SR-144258 did not
have any effect on the activity of 0-1812 as a-wave loss was 7±10 % which was similar
to 0-1812 alone treatment (7±12 %). SR-144258 also did not effect on 0-2545 action as
a-wave amplitude loss was 32±8%, similar to that of 0-2545 alone treatment (31±13%).
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Endocannabinoids preserve retinal cell density

Representative retinas from each group were analyzed for morphological changes
(Figure 24). The analysis of RGC count was limited to the retinal flat mounts because
the difficulty in obtaining consistent and comparable results with cross-sections. Also,
the retinal damage was not localized to a particular area; therefore, using cross sections to
assess morphological changes in the retina would have been less representative than the
retinal flat mounts. Retinal ganglionic cells were positively identified in the flat mounts
by comparing attributes (e.g. cell shape, distribution) with cross sections. After NMDA
injection RGC cell density was significantly reduced to 46.2±22.3 compared to 101±5.6
in the contralateral control (p<0.001). After treatment with 0-1812 or 0-2545 RGC cell
density was 76.4±12.1 and 67.4±6.5 respectively. Cell density was significantly greater
in the cannabinoid treated groups compared with NMDA alone (p=0.001). Also, both
cannabinoids were equally efficacious as both had a similar effect to prevent retinal cell
loss (p=0.58).

O-compounds inhibit Ca [2+] influx

In this pilot experiment the role of Ca [2+] influx as the mechanism of action for
neuroprotection was investigated. Experiments were performed on transformed rat retinal
ganglionic cells (RGC-5) with NMDA as a positive control. After NMDA (ImM)
treatment, cells were incubated with 10 uM of either 0-1812 or 0-2545 (Table 6). After
NMDA only treatment, the calcium signal after 60 min was 445% higher than baseline.
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With 0-1812 treatment, Ca [2+] influx was much less than that of NMD A alone after 60
min as the calcium signal was increased by 14%. After 0-2545 treatment, the calcium
signal was increased by 303% compared to baseline.

Discussion

Neuroprotection is an important strategy to combat the irreversible loss of retinal
ganglionic cells and eventually the optic nerve. While risk factors such as elevated IOP,
ischemia and genetics play an important role in the progression of retinal neuropathy,
they all share a common characteristic i.e. loss of loss of retinal cells especially the
ganglionic cells 26. While the specific trigger is unknown, experimental evidence
suggests that retinal cells undergo apoptosis26'140,168"170. Therapies that address both
neuroprotection and reduce risk factors offer the greatest potential to combat retinal
degenerative disorders.

In glaucoma, the most likely mechanism for retinal cell apoptosis is by
overstimulation of sodium channels, namely NMD A, that increase basal glutamate levels
leading to excitotoxicity23'26. In addition to NMDA channels, metabotropic receptors,
such as mGlu, can also elevate glutamate levels 17M73 . Excess glutamate via the NMDA
receptor increases intracellular Ca [2+] and targets the cell for apoptosis 23'26. NMDA
receptors, therefore, represent a therapeutic target for neuroprotection. In fact, NMDA
antagonists, such as MK801 and memantine, have shown to be neuroprotective in rat
ocular hypertensive models 1 1 9 ' 1 7 1 ' m . Memantine failed to show neuroprotection in
clinical trials.

Table 6: Percent increase in Ca [2+] influx in RGC-5 cells as a result of NMD A,
NMDA + O-1812 or NMDA + 0-2545 treatment

Baseline
15 min
30 min
60 min
A23187

NMDA
(ImM)
0
3
11
346
382

0-1812
(10 uM)
0
0
2
140
128

0-2545
(lOuM)
0
29
102
203
285

Untreated
0
8
13
150
351

118
It is desirable that new glaucoma drugs target the reduction of the risk factors,
such as elevated IOP, as well as preserve retinal cells from apoptosis. In chapter 7, the
IOP reduction potential of the synthetic O-compounds was demonstrated. The lipophilic
0-1812 reduced IOP to a greater extent than the hydrophilic 0-2545. Reduction of
intraocular pressure, while being a sound strategy for glaucoma treatment, does not treat
the underlying cause of glaucoma, retinal degeneration. Currently available drugs for
glaucoma only reduce IOP. Data from this study suggest that O-compounds are
neuroprotective, i.e. they retain the density and functionality of the photoreceptor and
ganglionic cells. In electroretinographic evaluation two weeks after NMDA treatment,
severe ERG a-wave deficits were observed. Concomitant treatment with either 0-1812
or 0-2545 reduced the a-wave amplitude loss, thereby preserving photoreceptor function.
This effect was significantly better after 0-1812 treatment than 0-2545. These findings
also corroborated with histology obtained from retinal flat mounts. Retinas from a
subsection of animals were removed and flat mounted and ganglionic cell density
determined two weeks after the induction of retinal damage by NMDA or after treatment
with NMDA + either 0-1812 or 0-2545. Both O-compounds mitigated the NMDA
induced ganglionic cell loss; however, 0-1812 was more efficacious.

In normotensive rabbits Song and Slowey speculated that cannabinoids such as
WIN 55212-2 exerted ocular effects in part through activation of CB1 receptors in the
eye 16. Studies designed to identify the distribution of cannabinoid receptor mRNA and
protein in ocular tissues support this hypothesis. Using reverse transcriptase polymerase
chain reaction technology, CB1 mRNA transcripts were expressed at significant amounts
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in the retina, ciliary body and iris but CB2 mRNA transcripts were undetectable in human
eyes 51. Likewise, a similar distribution of CB1 mRNA, with an absence of CB2 mRNA,
was found in eyes from ocular normotensive rats 13. CB1 receptors are widely distributed
in the eye. The local effect of cannabinoids at these receptors may be multifocal and
remains to be fully elucidated. While at the level of the ciliary body CB1 receptormediated control of IOP is likely due, at least partially, to decreased aqueous production,
their effect on neuroprotection is not fully understood 13 ' 147 ' 154 ' 155 . In our experiments,
the CB antagonists affected IOP reduction as well as neuroprotection. The CB1
antagonist blocked the neuroprotective action of 0-1812, a potent CB1 receptor agonist,
but had no effect on the action of 0-2545, a mixed CB receptor agonist. The CB2
receptor antagonist did not have an effect on the actions of either O-compound. These
results suggest that the neuroprotective effect could easily be mediated by the CB 1
receptor, which is similar to the proposed mechanism of IOP reduction. Kim et. al., have
also reported CB1 activation as a possible mechanism of neuroprotection against NMD A
toxicity 175.

Although both O-compounds exhibit similar affinities for the CB1 receptor, for
0-1812 (CB1 Ki= 3.4±0.5 nM, CB2 Kt = 3870±235 nM)79 and for 0-2545 (CB1 Kt =
1.5±0.2 nM, CB2 Kt = 0.32±0.02)87, the differences in effect can be attributed to
variabilities in ocular penetration. Receptor activation is a function of drug availability at
the target site. It well known that lipid soluble compounds have a constant and higher
bioavailability in the ocular environment than water soluble compounds
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. In chapter 6,

the ocular penetration of 0-1812 was shown to be greater than 0-2545. This variability

in ocular penetration affects both neuroprotection and IOP reduction potential. After a
single dose of 0-1812, a 2 nM concentration was maintained in the vitreous chamber for
120 minutes, while 0-2545 remained for only 80 minutes. Pretreatment with 0-1812 for
3 days prior and two days after NMD A injection, a concentration of at least 2 nM would
have been maintained in the vitreous chamber to mitigate the effects of NMD A. It is,
therefore, likely that a pharmacologic concentration might not have been achieved with
the hydrophilic drug to induce significant neuroprotection.

After NMD A injection, toxic effects can be observed in the retina in as little as 3
hours with a peak effect at 12 hours 177. In order for a drug to have an effect, a
pharmacological concentration must be achieved at the retina during the initial stages of
NMDA toxicity, i.e. within 3 hours. With topical (b.i.d) pretreatment for 3 days and an
additional 2 days after the NMDA injection, O-compounds were present in sufficient
concentration at the retina to mitigate the toxic effects of NMDA. When ERG
measurements were obtained after 1 week, the NMDA treated group showed a significant
loss in ERG function which continued to decline. In the presence of both O-compounds,
although there was some loss of function at 1 week, it improved over the period of 2
weeks. This phenomenon could be due to the toxic shock suffered by the retinal cells
which could disrupt, fragment or ablate retinal cells 178. Retinal function could also be
compromised due to the disruption of the osmotic balance after intravitreal injections
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It is important to note that even with a limited dosing regimen, substantial
neuroprotective effects were observed with either O-compound; however, 0-1812 was
significantly more effective.

.
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In an initial attempt to determine the mechanism of action, the role of intracellular
Ca [2+] influx was considered. In this pilot experiment, using isolated retinal ganglionic
cells, both O-compounds reduced the influx of Ca [2+]. This needs to be explored further
to identify downstream signalling events leading to apoptosis. In conclusion, Ocompounds are a new class of drugs that are efficacious ocular hypotensive and
neuroprotective agents. They can reduce the associated risk factors such as elevated IOP
and also address the underlying pathology of glaucoma by protecting retinal cells from
excitotoxic insults.
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CHAPTER IX

EFFECT OF COMBINING CANNABINOIDS WITH COMMONLY
PRESCRIBED GLAUCOMA MEDICATIONS ON INTRAOCULAR
PRESSURE IN A RAT OCULAR HYPERTENSIVE MODEL

Introduction

Despite the currently available therapeutic approaches for the treatment of
glaucoma, up to 50% of patients cannot be maintained on single drug therapy; most
require use of two or even three drugs to control their IOP 9T. Even the first line agent for
the treatment of glaucoma, timolol, as monotherapy controlled IOP in only 98 of 155
patients (63.2%) 34 . More recently, in the Ocular Hypertension Treatment Study, 40% of
patients randomized to treatment required more than one medication to achieve the 20%
reduction goal .

Commonly used classes of agents include (3-adrenergic antagonists e.g. timolol,
prostaglandin analogs e.g. latanoprost and a-adrenergic agonists e.g. brimonidine 98.
Timolol lowers IOP by decreasing aqueous humor production while brimonidine, in
addition to decreasing aqueous humor production, has the added benefit of increasing
uveoscleral outflow " . These two drugs when used concomitantly have an additive effect
on IOP

" . Other popular agents are carbonic anhydrase inhibitors e.g. dorzolamide

and prostaglandin analogs e.g. latanoprost. Dorzolamide reduces aqueous humor

formation while latanoprost increases uveoscleral outflow

'

. Endocannabinoid

analogs are a new class of agents that are efficacious ocular anti-hypertensives. These
analogs exert their effects by activating the cannabinoid receptor system (CB1/CB2).
Their exact mechanism of action is largely unknown. The purpose of this study is to
compare efficacy of timolol, dorzolamide, travoprost or brimonidine as monotherapy or
in combination with endocannabinoid analogs, 0-1812 or 0-2545, in a rat glaucoma
model.

Experimental design

Sprague Dawley rats were randomly assigned to receive 20 ul of either timolol
0.5%, 0-1812 1.0%, 0-2545 1.0%, brimonidine 0.2%, dorzolamide 2%, travoprost
0.004% alone or in combination, applied topically to the right eye. For combination
therapy, timolol 0.5%, dorzolamide 2.0% or brimonidine 0.1% were applied topically
followed 10 minutes later with either 0-1812 1.0% or 0-2545 1.0%. The contralateral
eye (OS) served as the untreated control. At the beginning of each experiment, animals
were sedated (ketamine 40 mg/kg and acepromazine 6 mg/kg) and baseline IOP, heart
rate (HR), blood pressure (BP) measurements (t=0) were obtained. IOP measurements
were obtained 30, 60 and 120 min after drug administration. HR and BP were also
measured at baseline and towards the end of the experiment. Before and at the
conclusion of each experiment, all eyes were examined and graded by slit lamp for signs

of ocular irritation.
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Figure 25: 0-1812 1.0% and timolol 0.5% were applied alone or in combination and
IOP recorded for 120 min.
Data are normalized to baseline measurements and presented as mean ± SEM.
* Significantly reduced compared to baseline (time = 0 min) (p<0.05),
f Significantly reduced compared to timolol and combination (p<0.05)
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Results
Combination of 0-1812 and timolol

Timolol and 0-1812 were administered alone or in combination to evaluate their
effect on IOP (Figure 25). At the beginning of the experiment, baseline IOP
measurements were obtained after which 0-1812 1.0% or timolol 0.5% was applied (time
= 0 min, baseline, n=4 per group). For combination treatment, timolol 0.5% was applied
first followed 10 minutes later with 0-1812 1.0% at baseline (t=0).

After 30 min, a single dose of timolol reduced IOP from 23±0.6 mmHg at
baseline to 16±0.8 mmHg, 0-1812 reduced IOP from a baseline of 27+1.2 mmHg to
17+0.9 mmHg while the combination resulted in an IOP of 19+0.6 mmHg from a
baseline of 27±1.0 mmHg (n=4). After this time point, no further reduction in IOP was
observed. After 60 min, IOP remained significantly reduced in all treatment groups when
compared to the baseline. However, IOP reduction achieved with 0-1812 was
significantly greater than that of timolol alone or the combination.

The experiment was terminated 120 min after drug administration. A final IOP
measurement of 20+0.4 mmHg was obtained in the timolol 0.5% treatment group, 18+0.4
mmHg for O-1812 1.0% and 21 ±0.5 mmHg for the combination. All treatments
significantly reduced IOP compared to baseline (p<0.05, n=4 per group). 0-1812 was
most efficacious compared with timolol or the fixed dose combination, no additive or
synergistic effects were observed after combination therapy.
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Figure 26: 0-1812 1.0% and dorzolamide 2% were applied alone or in combination and
IOP recorded for 120 min.
Data are normalized to baseline measurements and presented as mean ± SEM.
* Significantly reduced compared to baseline (time = 0 min) (p<0.05)
f Significantly reduced than the combination (p<0.05)
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Combination of 0-1812 and dorzolamide

The effects of dorzolamide and 0-1812 on IOP were evaluated when applied
alone or in combination (Figure 26). At the beginning of the experiment, baseline IOP
measurements were obtained after which 0-1812 1.0% or dorzolamide 2.0% was applied
(n=4 per group). For the combination treatment, dorzolamide 2.0% was applied first
followed 10 minutes later by 0-1812 1.0% at baseline (1=0).

After 30 min, dorzolamide alone reduced IOP from a baseline of 23±0.3 mmHg to
14±0.5 mmHg, 0-1812 reduced IOP from a baseline of 27+1.2 mmHg to 17+0.9 mmHg
while the combination treatment reduced IOP from a baseline of 24+1.1 mmHg to 19+1.2
mmHg (n=4). At this time point, combination of 0-1812 and dorzolamide did not
produce an additive or synergistic reduction in IOP.

After 60 min, dorzolamide had the greatest effect with an IOP of 13+1.2 mmHg
compared to 17+0.4 mmHg for 0-1812 and 17+0.5 mmHg for the combination.
Although significantly reduced from baseline, the effect of dorzolamide was not
sustained past 60 min. After 120 min, the IOP reduction achieved with 0-1812 alone and
the combination treatment was of a longer duration and greater than dorzolamide
treatment alone.
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Figure 27: 0-1812 1.0% and brimonidine 0.2% were applied alone or in combination
and IOP recorded for 120 min.
Data are normalized to baseline measurements and presented as mean ± SEM.
* Significantly reduced compared to baseline (time = 0 min) (p<0.05)
f Significantly reduced than brimonidine alone (p<0.05)
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Combination of 0-1812 and brimonidine

Brimonidine and 0-1812 were administered alone or in a fixed dose combination
to evaluate their effect on IOP (Figure 27). At the beginning of the experiment, baseline
IOP measurements were obtained after which 0-1812 1.0% or brimonidine 0.2% were
applied (n=4 per group). For combination treatment, brimonidine 0.2% was applied first
followed 10 minutes later with 0-1812 1.0% at baseline (1=0).

After 30 min, a single dose of brimonidine reduced IOP from a baseline of 23±1.5
mmHg to 16±1.1 mmHg, 0-1812 reduced IOP from a baseline of 27±1.2 mmHg to
17+0.9 mmHg while the combination treatment reduced IOP from a baseline of 25±0.8
mmHg to 14±0.7 mmHg (n=4). At this time point, the fixed dose combination
significantly reduced IOP compared to brimonidine alone but was not different than O1812 alone.

In all treatment groups, maximal effect was achieved 30 min after drug
administration after which IOP reverted towards baseline. At the end of the experiment
(120 min), IOP in the 0-1812 group (18±0.4 mmHg) and in the combination group
(21±1.2 mmHg) was still less than baseline. However, the brimonidine treatment group
returned to 22±0.5 mmHg, which was not significantly different from baseline (23±1.5
mmHg).
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Figure 28: 0-2545 1.0% and timolol 0.5% were applied alone or in combination and
IOP recorded for 120 min.
Data are normalized to baseline measurements and presented as mean ± SEM.
* Significantly reduced compared to baseline (time = 0 min) (p<0.05)
f Significantly reduced than combination (p<0.05)
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Combination of 0-2545 and timolol

The efficacy of timolol and 0-2545 when administered alone or in a fixed dose
combination was evaluated (Figure 28). At the beginning of the experiment, baseline
IOP measurements were obtained after which 0-2545 1.0% or timolol 0.5% were applied
(n=4 per group). For the combination treatment timolol 0.5% was applied first followed
10 minutes later with 0-2545 1.0% at baseline (time = 0 min, n=4 per group).

After 30 min, a single dose of timolol reduced IOP from 23±0.6 mmHg at
baseline to 16±0.8 mmHg, 0-2545 reduced IOP from 25+1.4 mmHg to 18±0.4 mmHg
while the combination resulted in a decline in IOP from 28±0.3 mmHg to 23±1.0 mmHg
(n=4). At this time point, the combination of 0-2545 and timolol was least efficacious
compared with 0-2545 or timolol alone.

Maximal efficacy for timolol and the combination was achieved after 30 min, and
after 60 min with 0-2545. At the end of the experiment (120 min) IOP remained
decreased in the 0-2545 group (18±0.5 mmHg) but tended to return toward baseline in
the timolol (20±0.4 mmHg) and the combination group (25±0.8 mmHg).
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Figure 29: 0-2545 1.0% and dorzolamide 2% were applied alone or in combination and
IOP recorded for 120 min.
Data are normalized to baseline measurements and presented as mean ± SEM.
* Significantly reduced compared to baseline (time = 0 min) (p<0.05)
f Significantly reduced than combination (p<0.05)
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Combination of 0-2545 with dorzolamide

The effects of dorzolamide and 0-2545 on IOP were evaluated when applied
alone or in combination (Figure 29). At the beginning of the experiment, baseline IOP
measurements were obtained after which 0-2545 1.0% or dorzolamide 2.0% were
applied (n=4 per group). For the combination treatment, dorzolamide 2.0% was applied
first followed 10 minutes later with 0-2545 1.0% (n=4).

After 30 min, a single dose of dorzolamide reduced IOP to 14±0.5 mmHg from a
baseline of 23±0.3 mmHg, 0-2545 reduced IOP to 18±0.4 mmHg from a baseline of
25+1.4 mmHg while the combination treatment reduced IOP to 20±0.6 mmHg from a
baseline of 28±0.6 mmHg (n=4). At this time point, dorzolamide was more efficacious
than either 0-2545 alone or the combination (p<0.05, n=4).

Dorzolamide treatment reduced IOP to 13±1.2 mmHg after 60 min and 0-2545
treatment reduced IOP to 18±1.0 mmHg, while their combined effect on IOP was only
26±0.4 mmHg. The combination treatment was least efficacious as IOP was not
significantly different than baseline after 60 and 120 min after administration. A final
IOP of 18±0.5 mmHg for 0-2545 and 19±0.3 mmHg for dorzolamide treatment were
recorded.
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Figure 30: 0-2545 1.0% and brimonidine 0.2% were applied alone or in combination
and IOP recorded for 120 min.
Data are normalized to baseline measurements and presented as mean ± SEM.
* Significantly reduced compared to baseline (time = 0 min) (p<0.05)
f Significantly reduced than brimonidine (p<0.05)
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Combination of 0-2545 with brimonidine

Brimonidine and 0-2545 were administered alone or in a fixed dose combination
to evaluate their effect on IOP (figure 30). At the beginning of the experiment, baseline
IOP measurements were obtained after which 0-2545 1.0% or brimonidine 0.2% were
applied (n=4 per group). For the combination treatment, brimonidine 0.2% was applied
first followed 10 minutes later with 0-1812 1.0% (n=4).

After 30 min, brimonidine reduced IOP from a baseline of 23±1.5 mmHg to
16±1.1 mmHg, 0-2545 reduced IOP from a baseline of 25+1.4 mmHg to 18±0.4 mmHg
while the combination treatment reduced IOP from a baseline of 27±0.9 mmHg to 17±1.3
mmHg (n=4). Although combination treatment reduced IOP beyond either drug alone, it
was not significant.

In all treatment groups, maximal effect was achieved 30 min after drug
administration, after which IOP reverted towards baseline measurements except for the
0-2545 group. At the end of the experiment (120 min), IOP reduction was sustained at
18±0.5 mmHg in the 0-2545 group and at 22±1.3 mmHg in the combination group.
However, the brimonidine treatment reverted to 22±0.5 mmHg which was not
significantly different from baseline (23±1.5 mmHg).
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Effect of travoprost on IOP

Travoprost was administered alone and IOP monitored for 120 min. After 60
min, IOP significantly increased from a baseline of 20.3±0.7 mmHg to 23.5±0.6 mmHg
(p=0.009, n=4). IOP returned to 20.5±0.6 mmHg after 120 min. Because of this variable
response in IOP, further combination study was not performed.

Discussion

Although increased IOP is not the sole risk factor for development and progresion
of glaucoma, therapies aimed at reducing IOP are beneficial for clinical management of
glaucoma 35,184 . It has been reported that even after a 1 mmHg reduction in IOP, the risk
for glaucoma progression decreases by 10% 2 . With currently available drugs, almost
75% of patients required combination therapy after 2 years of monotherapy

to achieve

a sufficient IOP reduction.

In this study, topical application of 0-1812 and 0-2545 was compared with
timolol, a B-adrenergic blocker and first line agent in glaucoma medical therapy 186"195.
The combined effect of 0-1812 1.0% and timolol 0.5% or 0-2545 1.0% and timolol
0.5% was significantly less from that of either drug alone suggesting that the combination
did not produce additive or synergistic effects. Additionally, timolol made no significant
contribution to the magnitude of the IOP reduction. It is therefore possible that the CB
agonists may in some fashion draw on a receptor population that includes those affected
by timolol. Vasquez et al have demonstrated that CB receptors can reduce beta
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adrenergic receptor activity through G protein modulated effects, thus mimicking beta
adrenergic blockade
Dorzolamide is a carbonic anhydrase inhibitor. The exact mechanism of action of
dorzolamide is unclear 197. Vasodilation associated with dorzolamide is independent of
pH changes in ocular vessels and activation of nilxic oxide 198'199. Although, carbonic
anhydrase inhibitors decrease capillary extracellular pH, the vasodilator effect might be
potentiated by relaxation of capillary pericytes 20°. When administered alone,
dorzolamide was as effective as 0-1812 initially in reducing IOP but the duration of
effect was short-lived. Dorzolamide was more effective than 0-2545. When combined
with either 0-1812 or 0-2545, no additive or synergistic effects were observed. In fact,
the combination therapy had less on IOP than either drug alone. When combined with O1812, IOP was sustained for up to 120 min, an effect similar to that of 0-1812 alone. The
sustainability of effect with the combination can be mostly attributed to 0-1812, a potent
CB1 agonist. In comparison, the duration was shorter with dorzolamide and 0-2545. A
suggestion for the stunted effect might be that since 0-2545 is a mixed CB agonist, it
might not be able to activate enough CB1 receptors. Although reports on this topic are
scarce, Maor et al has suggested that cannabinoids do not inhibit carbonic anhydrase, this
needs further study 201.

The a-adrenergic agonists initially reduce aqueous humor production202"204 and
increase uveoscleral outflow after chronic application " . In this rat glaucoma model,
brimonidine alone was the least effective agent in terms of potency and duration of effect.
When combined with 0-1812, IOP was less than after brimonidine alone but was similar

to that after 0-1812 alone. When combined with 0-2545, the initial reduction in IOP
appeared to be additive, but the duration of effect was short lived. Brimonidine lowers
IOP by both reducing aqueous humor production and increasing uveoscleral outflow and
therefore has the theoretical advantage over other medications. However, in numerous
studies, brimonidine alone treatment was not as efficacious and not well tolerated .
Indeed, in our rat glaucoma model, brimonidine was the least effective agent especially
when administered in combination with cannabinoids. In the presence of cannabinoids,
the common G-proteins shared by both cannabinoid and a-adrenergic agonists might be
redistributed 205.

Prostaglandin analogs are also emerging as conventional drugs for glaucoma
1(\f\ 0CV7

management

'

. In addition to its effect on IOP, it can also influence cyclo9f)8 OCiQ

oxygenase 2 and nitric oxide synthase to confer neuroprotection

'

. Administration

of travoprost in our rat glaucoma model actually increased IOP, and, therefore, was
deemed unsuitable for the combination experiments. In other reports, prostaglandin
analogs have been shown to elicit a bi-phasic IOP response in rodent models, i.e. an
initial increase followed by a decline in IOP 210.
In this study, both 0-1812 and 0-2545 were most effacacious when administered
alone. There were no synergistic or additive effects on IOP when combined with timolol,
brimonidine or dorzolamide.

CHAPTER X
CONCLUSIONS

It has been over a decade since a new class of pharmacologic agents was
introduced for the clinical management of glaucoma25. The currently available drugs to
treat glaucoma primarily reduce the risk factor of elevated intraocular pressure. These
drugs have not shown to be neuroprotective, which would address the underlying
pathology present in glaucoma, as well as a number of other retinal degenerative
disorders. That being said, it is true that therapies aimed at reducing IOP are beneficial
for clinical management of glaucoma35'184. Even a 1 mmHg reduction in IOP reduces
the risk for glaucoma progression by 10% 2. With currently available drugs, almost 75%
of patients required combination therapy after 2 years to achieve a suitable IOP reduction
185

. This is an indication that there is a need for more efficacious drugs and for new

therapuetic targets.

In this dissertation, newly synthesized cannabinoids, 0-1812 and 0-2545, were
studied for their ability to decrease IOP and neuroprotective effects. The first aim with
these new cannabinoids was to determine the pharmacokinetics after topical
administration. Using in vivo microdialysis, continuous sampling of the aqueous and
vitreous is possible to determine pharmacokinetic profiles of both the lipid (0-1812) and
water soluble (0-2545) cannabinoids. After a single topical administration, 0-1812
effectively penetrated both the anterior and posterior chamber and was maintained for at
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least 120 min. 0-2545, being water-soluble, also penetrated both the ocular chambers,
but was eliminated more rapidly than 0-1812.

Before studying the IOP effects in the eye, a stable ocular hypertensive model that
mimics human glaucoma had to be developed. Limitations with currently available
models prompted us to develop a technique in which careful attention was given to
minimizing surgical trauma, primarily by identifying the vortex vessels directly through
the conjunctiva and then ligating them using only very small minimal incisions. We
hypothesized that the greater the surgical insult, the faster and more extensive the
development of collateral circulation, which would defeat the attempt to elevate IOP. It
was crucial that incisions of the conjunctiva be limited to the immediate area of the
vortex veins. Ligation rather than cautery of vortex veins was essential. Collateral
circulation was more extensive when cautery alone or cautery following ligation was
used. It is possible that the use of cautery alone is a sufficient local insult to stimulate the
formation of collaterals. Following ligation of three of the four vortex veins, a steady
elevation was achieved without negative impact on other ocular structures except for the
retina. After ligation, IOP increased gradually and was sustained for up to a year. This
Sprague Dawley rat model was also remarkably free of postoperative complications and
responded well to standard pharmacotherapy with timolol.

Using this ocular hypertensive model in specific aim # 2, the ability of newly
synthesized 0-1812 and 0-2545 to decrease IOP was found to be comparable to or even
greater than WIN 55212-2, a widely studied cannabinoid and timolol, a B-adrenergic

blocker and first line agent in glaucoma medical therapy

" . The ability of the

cannabinoids to reduce IOP is mediated primarily by CB1 receptor activation. This can
be concluded by using CB receptor specific antagonists. In the presence of CB1
antagonist, SR141716, the magnitude and duration of cannabinoid mediated hypotensive
effect was severely diminished.

Once the potential to reduce IOP was realized, the neuroprotective effect of these
O-compounds was studied in specific aim # 3. In this study the ERG was used as an endpoint to evaluate retinal function based on the a-wave amplitude. The ERG a-wave
represents the outer retinal response, which is generated by the photoreceptors and
bipolar cells ay'Ail. The a-wave amplitude was preserved after treatment with both O1812 and 0-2545 when compared to NMDA alone treatment. However, 0-1812 was
more efficacious than 0-2545. Retinas from a subsection of animals were removed and
examined histologically. Our ERG findings corroborated with histology. Although both
O-compounds were equally efficacious in preventing retinal ganglionic cell loss, data
from both IOP as well as ERG suggests that among the O-compounds, 0-1812 is more
efficacious than 0-2545.

In this study the electroretinogram was used as an end-point to evaluate retinal
function based on the a-wave amplitudes. The ERG a-wave represents the outer retinal
response which is generated by the photoreceptors and bipolar cells 89 ' 2U . The rods and
cones with impulses from their respective bipolar cells contribute to the corneal positive
and negative responses of the ERG a-wave 212. However, majority of the a-wave
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amplitude is derived from the rods rather than the cones

. The outer retinal response

can be isolated by bright light stimulus 8 9 ' 2 n . Although this technique is gaining
popularity, analysis and interpretation of ERG data are currently not standardized. We
are solely relying on the amplitude changes of the a-wave and not the latency of the peak
largely due to the fact that the exact mechanisms that generate the a- or b-waves have not
been fully elucidated. As a result, these findings cannot be translated directly in the
human glaucoma condition. In this experiment, discrepancies in ERG a-wave response
after NMDA damage were obvious within the first week. In some instances,
photoreceptor damage did not register electrically with the full-field system and therefore
was not used as part of the analysis. Fortunately, after two weeks, ERG responses had
stabilized and differences between the treated and untreated eyes could be easily
quantitated.

While this study solely focused on the health of the photoreceptors, the next
logical step is to study the effects on the retinal ganglionic cells. The full-field ERG
modality alone is not sufficient to assess ganglionic cell function, a more sophisticated
ERG modality, such as a multifocal electroretinogram should be employed. With this
technique, a functional map of the retina can be obtained in vivo. Regardless of the
technological sophistication, the use of any ERG modality is still preferred over the
conventional histological techniques because it is possible to monitor the progression of
the disease as well as treatment effectiveness over time. A standard histological
technique to count retinal cells involves an invasive procedure in which the optic nerve is
transected and fluoro-gold injected at the transection site. The animal is then kept alive

for 48 hrs after which it is euthanized and the retinas flat mounted. This technique
introduces a myriad of variables, for e.g. during the 48 hrs, the animal is rendered blind
and loses the ability to feed itself, the dye itself is absorbed into the brain causing other
CNS deficits. All of these side effects are not desirable.

Despite the currently available therapeutic approaches for the treatment of
glaucoma, up to 50% of patients cannot be maintained on single drug therapy; most
require use of two or even three drugs to control their IOP 9T. In additional experiments,
the combined efficacy of cannabinoids with timolol, dorzolamide or brimonidine was
compared in our rat glaucoma model. Travoprost was also used but did not change the
IOP after a single dose. In this study, both 0-1812 and 0-2545 were most effacacious
when administered alone. There were no synergistic or additive effects on IOP when
combined with timolol, brimonidine or dorzolamide. Because of the efficacy of the Ocompounds, they hold tremendous potential as monotherapy in patients who do not
respond to currently available medications.

Glaucoma is a complex disease and its current limited therapeutic management
suggests the need for neuroprotective intervention. While this neuroprotective strategy is
sound, its realization requires dealing with complex signal transduction events that have
unresolved mechanisms. However, data from this dissertation supports cannabinoids as a
new class of drugs that have shown great potential for monotherapy, having both
neuroprotective and anti-hypertensive effects. These initial observations need to be
further confirmed in other animal models before they receive clinical evaluation. Future
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investigations will focus on the determining the mechanisms of neuroprotection and
development of new cannabinoid and non-cannabinoid analogs.

145
BIBLIOGRAPHY

1.

The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between
control of intraocular pressure and visual field deterioration.The AGIS
Investigators. Am J Ophthalmol 2000;130:429-440.

2.

Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction
of intraocular pressure and glaucoma progression: results from the Early Manifest
Glaucoma Trial. Arch Ophthalmol 2002;120:1268-1279.

3.

Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol
1998;359:1-18.

4.

ElSohly MA, Grotenhermen, F., Russo, E. Cannabis and cannabinoids.
Pharmacology, toxicology and therapeutic potential. New York: Haworth Press;
2002:27-36.

5.

Tomida I, Pertwee RG, Azuara-Blanco A. Cannabinoids and glaucoma. Br J
Ophthalmol 2004;88:708-713.

6.

Hepler RS, Frank IR. Marihuana smoking and intraocular pressure. Jama
1971;217:1392.

7.

Brown B, Adams AJ, Haegerstrom-Portnoy G, Jones RT, Flom MC. Pupil size
after use of marijuana and alcohol. Am J Ophthalmol 1977;83:350-354.

8.

Aryana A, Williams MA. Marijuana as a trigger of cardiovascular events:
speculation or scientific certainty? Int J Cardiol 2007; 118:141-144.

146
9.

Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin
Pharmacokinet 2003;42:327-360.

10.

Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology.
XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54:161202.

11.

Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins
Leukot Essent Fatty Acids 2002;66:101-121.

12.

Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol
Ther 1997;74:129-180.

13.

Porcella A,Casellas P, Gessa GL, Pani L. Cannabinoid receptor CB1 mRNA is
highly expressed in the rat ciliary body: implications for the antiglaucoma
properties of marihuana. Brain Res Mol Brain Res 1998;58:240-245.

14.

Straiker AJ, Maguire G, Mackie K, Lindsey J. Localization of cannabinoid CB1
receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci
1999;40:2442-2448.

15.

Allen RC, Sheppard IJD, Lattanzio F, Jr., Lichtman A, Crouch E, Jr., Williams P.
Ocular and Systemic Effects of WIN 55-212-2 in Normotensive Rabbits. Invest
Ophthalmol Vis Sci 2003;44:4423-.

16.

Song ZH, Slowey CA. Involvement of cannabinoid receptors in the intraocular
pressure-lowering effects of WIN55212-2. J Pharmacol Exp Ther 2000;292:136139.

17.

Blanc JP, Molteno AC, Fuller JR, Bevin TH, Herbison P. Life expectancy of
patients with neovascular glaucoma drained by Molteno implants. Clin
Experiment Ophthalmol 2004;32:360-363.

18.

McCarty CA, Nanjan MB, Taylor HR. Vision impairment predicts 5 year
mortality. Br J Ophthalmol 2001;85:322-326.

19.

Vu HT, Keeffe JE, McCarty CA, Taylor HR. Impact of unilateral and bilateral
vision loss on quality of life. Br J Ophthalmol 2005;89:360-363.

20.

Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual
impairment among adults in the United States. Arch Ophthalmol 2004; 122:477485.

21.

Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol
1996;80:389-393.

22.

Sugrue MF. New approaches to antiglaucoma therapy. J Med Chem
1997;40:2793-2809.

23.

El-Remessy AB, Khalil IE, Matragoon S, et al. Neuroprotective effect of ()Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced

148
retinal neurotoxicity: involvement of peroxynitrite. Am J Pathol 2003; 163:19972008.
24.

Dreyer EB, Lipton SA. New perspectives on glaucoma. Jama 1999;281:306-308.

25.

Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on
circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure
in patients with glaucoma. Invest Ophthalmol Vis Sci 2006;47:2917-2923.

26.

Weinreb RN, Levin LA. Is neuroprotection a viable therapy for glaucoma? Arch
Ophthalmol 1999;117:1540-1544.

27.

Osborne NN, Wood JP, Chidlow G, Bae JH, Melena J, Nash MS. Ganglion cell
death in glaucoma: what do we really know? Br J Ophthalmol 1999;83:980-986.

28.

Dueker DK, Singh K, Lin SC, et al. Corneal thickness measurement in the
management of primary open-angle glaucoma: a report by the American
Academy of Ophthalmology. Ophthalmology 2007;114:1779-1787.

29.

Gong G, Kosoko-Lasaki S, Haynatzki G, Lynch HT, Lynch JA, Wilson MR.
Inherited, familial and sporadic primary open-angle glaucoma. J Natl Med Assoc
2007;99:559-563.

30.

Kniestedt C, Lin S, Choe J, et al. Correlation between intraocular pressure, central
corneal thickness, stage of glaucoma, and demographic patient data: prospective
analysis of biophysical parameters in tertiary glaucoma practice populations. J
Glaucoma 2006;15:91-97.

149
31.

Kwon YH, Kim YI, Pereira ML, Montague PR, Zimmerman MB, Alward WL.
Rate of optic disc cup progression in treated primary open-angle glaucoma. J
Glaucoma 2003;12:409-416.

32.

Leske MC. The epidemiology of open-angle glaucoma: a review. Am J Epidemiol
1983;118:166-191.

33.

Weih LM, Nanjan M, McCarty CA, Taylor HR. Prevalence and predictors of
open-angle glaucoma: results from the visual impairment project. Ophthalmology
2001;108:1966-1972.

34.

Uusitalo RJ, Palkama A. Long-term evaluation of timolol. Acta Ophthalmol
(Copenh) 1989;67:573-581.

35.

Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension
Treatment Study: a randomized trial determines that topical ocular hypotensive
medication delays or prevents the onset of primary open-angle glaucoma. Arch
Ophthalmol 2002;120:701-713; discussion 829-730.

36.

The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus
topical medicines. The Glaucoma Laser Trial Research Group. Ophthalmology
1990;97:1403-1413.

37.

Forbes M, Bansal RK. Argon laser goniophotocoagulation of the trabecular
meshwork in open-angle glaucoma. Trans Am Ophthalmol Soc 1981;79:257-275.

150
38.

Homs DJ, Bellows AR, Hutchinson BT, Allen RC. Argon laser trabeculoplasty
for open angle glaucoma. A retrospective study of 380 eyes. Trans Ophthalmol
Soc UK 1983;103 (Pt 3):288-296.

39.

Klein HZ, Shields MB, Ernest JT. Two-stage argon laser trabeculoplasty in openangle glaucoma. Am J Ophthalmol 1985;99:392-395.

40.

Hodges LC, Reggio PH, Green K. Evidence against cannabinoid receptor
involvement in intraocular pressure effects of cannabinoids in rabbits. Ophthalmic
Res 1997;29:1-5.

41.

Naveh N, Weissman C, Muchtar S, Benita S, Mechoulam R. A submicron
emulsion of HU-211, a synthetic cannabinoid, reduces intraocular pressure in
rabbits. Graefes Arch Clin Exp Ophthalmol 2000;238:334-338.

42.

Green KE, Kearse CE. Ocular penetration of topical Delta9-tetrahydrocannabinol
from rabbit corneal or cul-de-sac application site. Curr Eye Res 2000;21:566-570.

43.

Kearse EC, Green K. Effect of vehicle upon in vitro transcorneal permeability and
intracorneal content of Delta9-tetrahydrocannabinol. Curr Eye Res 2000;20:496501.

44.

Pate DW, Jarvinen K, Urtti A, Mahadevan V, Jarvinen T. Effect of the CB1
receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in

normotensive rabbits. Life Sci 1998;63:2181-2188.

151
45.

Juntunen J, Jarvinen T, Niemi R. In-vitro corneal permeation of cannabinoids and
their water-soluble phosphate ester prodrugs. JPharm Pharmacol 2005;57:11531157.

46.

Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury:
therapeutic implications. Trends Mol Med 2002;8:58-61.

47.

Reistad T, Mariussen E, Ring A, Fonnum F. In vitro toxicity of
tetrabromobisphenol-A on cerebellar granule cells: cell death, free radical
formation, calcium influx and extracellular glutamate. Toxicol Sci 2007;96:268278.

48.

Sanelli T, Ge W, Leystra-Lantz C, Strong MJ. Calcium mediated excitotoxicity in
neurofilament aggregate-bearing neurons in vitro is NMDA receptor dependant. J
Neurol Sci 2007;256:39-51.

49.

Sasaki T, Kaneko A. Elevation of intracellular ca(2+) concentration induced by
hypoxia in retinal ganglion cells. Jpn J Ophthalmol 2007;51:175-180.

50.

Ullian EM, Barkis WB, Chen S, Diamond JS, Barres BA. Invulnerability of
retinal ganglion cells to NMDA excitotoxicity. Mol Cell Neurosci 2004;26:544557.

51.

Porcella A, Maxia C, Gessa GL, Pani L. The human eye expresses high levels of

CB1 cannabinoid receptor mRNA and protein. Eur J Neurosci 2000;12:11231127.

152
52.

Stamer WD, Golightly SF, Hosohata Y, et al. Cannabinoid CB(1) receptor
expression, activation and detection of endogenous ligand in trabecular meshwork
and ciliary process tissues. Eur J Pharmacol 2001;431:277-286.

53.

Zhong L, Geng L, Njie Y, Feng W, Song ZH. CB2 cannabinoid receptors in
trabecular meshwork cells mediate JWHO15-induced enhancement of aqueous
humor outflow facility. Invest Ophthalmol Vis Sci 2005;46:1988-1992.

54.

Karlsen RL, Fonnum F. The toxic effect of sodium glutamate on rat retina:
changes in putative transmitters and their corresponding enzymes. JNeurochem
1976;27:1437-1441.

55.

Takasaki Y. Studies on brain lesion by administration of monosodium Lglutamate to mice. I. Brain lesions in infant mice caused by administration of
monosodium L-glutamate. Toxicology 1978;9:293-305.

56.

Wiley JL, LaVecchia KL, Karp NE, et al. A comparison of the discriminative
stimulus effects of delta(9)-tetrahydrocannabinol and 0-1812, a potent and
metabolically stable anandamide analog, in rats. Exp Clin Psychopharmacol
2004;12:173-179.

57.

Personne J. Rapport sur le concours relatif a l'analyse du chanvre. JPharm Chim
1855;28:461-463.

58.

Vignolo G. Sull'essenza di Cannabis indica. Gazetta Chimica Italiana 1895;262268.

59.

Mechoulam R, Harms L. A historical overview of chemical research on
cannabinoids. Chem Phys Lipids 2000; 108:1-13.

60.

Mechoulam R, Gaoni Y. The absolute configuration of delta-1tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett
1967;12:1109-1111.

61.

Archer RA, Stark, P., Lemberger, L. Nabilone. Boca Raton, FL: CRC Press;
1986:86-103.

62.

Howlett AC, Johnson MR, Melvin LS, Milne GM. Nonclassical cannabinoid
analgetics inhibit adenylate cyclase: development of a cannabinoid receptor
model. MolPharmacol 1988;33:297-302.

63.

Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a
cannabinoid receptor and functional expression of the cloned cDNA. Nature
1990;346:561-564.

64.

Chakrabarti A, Onaivi ES, Chaudhuri G. Cloning and sequencing of a cDNA
encoding the mouse brain-type cannabinoid receptor protein. DNA Seq
1995;5:385-388.

65.

Gerard CM, Mollereau C, Vassart G, Parmentier M. Molecular cloning of a
human cannabinoid receptor which is also expressed in testis. Biochem J
1991;279(Pt 1):129-134.

154
66.

Gerard C, Mollereau C, Vassart G, Parmentier M. Nucleotide sequence of a
human cannabinoid receptor cDNA. Nucleic Acids Res 1990;18:7142.

67.

Griffin G, Tao Q, Abood ME. Cloning and pharmacological characterization of
the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther 2000;292:886-894.

68.

Shire D, Calandra B, Rinaldi-Carmona M, et al. Molecular cloning, expression
and function of the murine CB2 peripheral cannabinoid receptor. Biochim
BiophysActa 1996;1307:132-136.

69.

Rinaldi-Carmona M, Calandra B, Shire D, et al. Characterization of two cloned
human CB1 cannabinoid receptor isoforms. J Pharmacol Exp Ther 1996;278:871878.

70.

Song ZH, Bonner TI. A lysine residue of the cannabinoid receptor is critical for
receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol
1996;49:891-896.

71.

Chin CN, Lucas-Lenard J, Abadji V, Kendall DA. Ligand binding and modulation
of cyclic AMP levels depend on the chemical nature of residue 192 of the human
cannabinoid receptor X.JNeurochem 1998;70:366-373.

72.

Tao Q, McAllister SD, Andreassi J, et al. Role of a conserved lysine residue in the
peripheral cannabinoid receptor (CB2): evidence for subtype specificity. Mol

Pharmacol 1999;55:605-613.

73.

Devane WA, Breuer A, Sheskin T, Jarbe TU, Eisen MS, Mechoulam R. A novel
probe for the cannabinoid receptor. J Med Chem 1992;35:2065-2069.

74.

Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2monoglyceride, present in canine gut, that binds to cannabinoid receptors.
Biochem Pharmacol 1995;50:83-90.

75.

Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible
endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun
1995;215:89-97.

76.

Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, Vogel Z. The
peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein
coupling. FEBSLett 1995;375:143-147.

77.

Griffin G, Atkinson PJ, Showalter VM, Martin BR, Abood ME. Evaluation of
cannabinoid receptor agonists and antagonists using the guanosine-5'-0-(3[35S]thio)-triphosphate binding assay in rat cerebellar membranes. J Pharmacol
Exp Ther 1998;285:553-560.

78.

Pertwee RG. Pharmacology of cannabinoid receptor ligands. Curr Med Chem
1999;6:635-664.

79.

Di Marzo V, Bisogno T, De Petrocellis L, et al. Highly selective CB(1)

cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid"
ligands. Biochem Biophys Res Commun 2001;281:444-451.

156
80.

Martin BR, Mechoulam R, Razdan RK. Discovery and characterization of
endogenous cannabinoids. Life Sci 1999;65:573-595.

81.

Wiley JL, Smith FL, Razdan RK, Dewey WL. Task specificity of cross-tolerance
between Delta9-tetrahydrocannabinol and anandamide analogs in mice. Eur J
Pharmacol 2005;510:59-68.

82.

Wallace MJ, Martin BR, DeLorenzo RJ. Evidence for a physiological role of
endocannabinoids in the modulation of seizure threshold and severity. Eur J
Pharmacol 2002;452:295-301.

83.

Wilson DM, Varvel SA, Harloe JP, Martin BR, Lichtman AH. SR 141716
(Rimonabant) precipitates withdrawal in marijuana-dependent mice. Pharmacol
Biochem Behav 2006;85:105-113.

84.

Lichtman AH, Martin BR. Cannabinoid-induced antinociception is mediated by a
spinal alpha 2-noradrenergic mechanism. Brain Res 1991;559:309-314.

85.

Lichtman AH, Martin BR. Spinal and supraspinal components of cannabinoidinduced antinociception. J Pharmacol Exp Ther 1991;258:517-523.

86.

Zitko BA, Howes JF, Razdan RK, et al. Water-soluble derivatives of 1 tetrahydrocannabinol. Science 1972;177:442-444.

87.

Martin BR, Wiley JL, Beletskaya I, et al. Pharmacological characterization of
novel water-soluble cannabinoids. J Pharmacol Exp Ther 2006;318:1230-1239.

157

88.

Singer M, Ryan WJ, Saha B, Martin BR, Razdan RK. Potent cyano and
carboxamido side-chain analogues of 1', r-dimethyl-delta8-tetrahydrocannabinol.
JMedChem 1998;41:4400-4407.

89.

Fortune B, Bui BV, Morrison JC, et al. Selective ganglion cell functional loss in
rats with experimental glaucoma. Invest Ophthalmol Vis Sci 2004;45:1854-1862.

90.

Hosseini A, Lattanzio FA, Williams PB, Tibbs D, Samudre SS, Allen RC.
Chronic topical administration of WIN-55-212-2 maintains a reduction in IOP in
a rat glaucoma model without adverse effects. Exp Eye Res 2006;82:753-759.

91.

Samudre S CI, Hosseini A., Lattanzio, Jr F., Allen R., Williams P. Development
of a Stable Rat Ocular Hypertension Model. Invest Ophthalmol Vis Sci 2004;45.

92.

Samudre SS, Tibbs D, Lattanzio FA, Jr., et al. Chronic Application of Topical
WIN 55-212-2 in a Rat Glaucoma Model. Invest Ophthalmol Vis Sci
2005;46:3784-.

93.

Rittenhouse KD, Peiffer RL, Jr., Pollack GM. Evaluation of microdialysis
sampling of aqueous humor for in vivo models of ocular absorption and
disposition. JPharm BiomedAnal 1998;16:951-959.

94.

Barberi-Heyob M, Merlin JL, Krakowski I, Kettani C, Collin E, Poulain P.
[Plasma pharmacokinetics of morphine and morphine-6-glucuronide using high
performance liquid chromatography and colorimetric detection]. Bull Cancer
1991;78:1063-1070.

158
95.

Barberi-Heyob M, Merlin JL, Weber B. Determination of 5-fluorouracil and its
main metabolites in plasma by high-performance liquid chromatography. J
Chromatogr 1992;573:247-252.

96.

Samudre SS, Williams PB, Martin BR, Castillo IG, Hosseini A, Lattanzio FA, Jr.
Novel Endocannabinoids Confer Neuroprotection in NMDA Rat Model. Invest
Ophthalmol Vis Sci 2006;47:1566-.

97.

Kobelt-Nguyen G, Gerdtham UG, Aim A. Costs of treating primary open-angle
glaucoma and ocular hypertension: a retrospective, observational two-year chart
review of newly diagnosed patients in Sweden and the United States. J Glaucoma
1998;7:95-104.

98.

Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5%
timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in
patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch
Ophthalmol 2006;124:1230-1238.

99.

Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of
brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J
Ophthalmol 1999;128:8-14.

100.

Avila MY, Seidler RW, Stone RA, Civan MM. Inhibitors of NHE-1 Na+/H+
exchange reduce mouse intraocular pressure. Invest Ophthalmol Vis Sci
2002;43:1897-1902.

159
101.

Garcia-Sanchez J, Rouland JF, Spiegel D, et al. A comparison of the fixed
combination of latanoprost and timolol with the unfixed combination of
brimonidine and timolol in patients with elevated intraocular pressure. A six
month, evaluator masked, multicentre study in Europe. Br J Ophthalmol
2004;88:877-883.

102.

Cohan BE, Bohr DF. Goldmann applanation tonometry in the conscious rat.
Invest Ophthalmol Vis Sci 2001;42:340-342.

103.

Hogan MJ, Kimura SJ, Thygeson P. Signs and symptoms of uveitis. I. Anterior
uveitis. Am J Ophthalmol 1959;47:155-170.

104.

Samudre SS, Lattanzio FA, Jr., Williams PB, Sheppard JD, Jr. Comparison of
topical steroids for acute anterior uveitis. J Ocul Pharmacol Ther 2004;20:533547.

105.

Krishnamoorthy RR, Agarwal P, Prasanna G, et al. Characterization of a
transformed rat retinal ganglion cell line. Brain Res Mol Brain Res 2001;86:1-12.

106.

Quigley HA. Neuronal death in glaucoma. Prog Retin Eye Res 1999;18:39-57.

107.

Allen RC. Principles and Practice of Ophthalmology. 2nd ed. Philadelphia, PA:
WB Saunders; 2000:2891-2916.

108.

Ederer F, Gaasterland DA, Dally LG, et al. The Advanced Glaucoma Intervention
Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year
results. Ophthalmology 2004;111:651-664.

160
109.

Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for
glaucoma progression and the effect of treatment: the early manifest glaucoma
trial. Arch Ophthalmol 2003;121:48-56.

110.

Miglior S, Zeyen T, Pfeiffer N, Cunha-Vaz J, Torri V, Adamsons I. Results of the
European Glaucoma Prevention Study. Ophthalmology 2005;112:366-375.

111.

Benozzi J, Nahum LP, Campanelli JL, Rosenstein RE. Effect of hyaluronic acid
on intraocular pressure in rats. Invest Ophthalmol Vis Sci 2002;43:2196-2200.

112.

Morrison JC, Moore CG, Deppmeier LM, Gold BG, Meshul CK, Johnson EC. A
rat model of chronic pressure-induced optic nerve damage. Exp Eye Res
1997;64:85-96.

113.

Johnson EC, Deppmeier LM, Wentzien SK, Hsu I, Morrison JC. Chronology of
optic nerve head and retinal responses to elevated intraocular pressure. Invest
Ophthalmol Vis Sci 2000;41:431-442.

114.

Jia L, Cepurna WO, Johnson EC, Morrison JC. Patterns of intraocular pressure
elevation after aqueous humor outflow obstruction in rats. Invest Ophthalmol Vis
Sci 2000;41:1380-1385.

115.

Jia L, Cepurna WO, Johnson EC, Morrison JC. Effect of general anesthetics on
IOP in rats with experimental aqueous outflow obstruction. Invest Ophthalmol Vis
Sci 2000;41:3415-3419.

161
116.

Chauhan BC, Pan J, Archibald ML, LeVatte TL, Kelly ME, Tremblay F. Effect of
intraocular pressure on optic disc topography, electroretinography, and axonal
loss in a chronic pressure-induced rat model of optic nerve damage. Invest
Ophthalmol Vis Sci 2002;43:2969-2976.

117.

Levkovitch-Verbin H, Quigley HA, Martin KR, Valenta D, Baumrind LA, Pease
ME. Translimbal laser photocoagulation to the trabecular meshwork as a model of
glaucoma in rats. Invest Ophthalmol Vis Sci 2002;43:402-410.

118.

WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal
ganglion cells by brimonidine in rats with laser-induced chronic ocular
hypertension. Invest Ophthalmol Vis Sci 2001;42:2849-2855.

119.

Hare W, WoldeMussie E, Lai R, et al. Efficacy and safety of memantine, an
NMDA-type open-channel blocker, for reduction of retinal injury associated with
experimental glaucoma in rat and monkey. Surv Ophthalmol 2001;45 Suppl
3:S284-289; discussion S295-286.

120.

Karim MZ, Gu Z, Sawada A, et al. Neuroprotective effects of R(-)-l(benzo[b]thiophen-5-yl)-2- [2-(N,N-diethylamino)ethoxy]ethanol hydrochloride
(T-588) against retinal ganglion cell death induced by elevated intraocular
pressure in rat. Jpn J Ophthalmol 2002;46:621-626.

121.

Ueda J, Sawaguchi S, Hanyu T, et al. Experimental glaucoma model in the rat
induced by laser trabecular photocoagulation after an intracameral injection of
India ink. Jpn J Ophthalmol 1998;42:337-344.

162
122.

Sawada A, Neufeld AH. Confirmation of the rat model of chronic, moderately
elevated intraocular pressure. Exp Eye Res 1999;69:525-531.

123.

Grozdanic SD, Betts DM, Sakaguchi DS, Allbaugh RA, Kwon YH, Kardon RH.
Laser-induced mouse model of chronic ocular hypertension. Invest Ophthalmol
Vis Sci 2003;44:4337-4346.

124.

Grozdanic SD, Betts DM, Sakaguchi DS, Kwon YH, Kardon RH, Sonea IM.
Temporary elevation of the intraocular pressure by cauterization of vortex and
episcleral veins in rats causes functional deficits in the retina and optic nerve. Exp
Eye Res 2003;77:27-33.

125.

Mittag TW, Danias J, Pohorenec G, et al. Retinal damage after 3 to 4 months of
elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci
2000;41:3451-3459.

126.

Yu S, Tanabe T, Yoshimura N. A rat model of glaucoma induced by episcleral
vein ligation. Exp Eye Res 2006;83:758-770.

127.

Hu M, Nicolson GL, Trent JC, 2nd, et al. Characterization of 11 human sarcoma
cell strains: evaluation of cytogenetics, tumorigenicity, metastasis, and production
of angiogenic factors. Cancer 2002;95:1569-1576.

128.

Takahashi K, Kishi S. Remodeling of choroidal venous drainage after vortex vein
occlusion following scleral buckling for retinal detachment. Am J Ophthalmol
2000;129:191-198.

129.

Saito K, Kim HS, Sakai N, Ishizuka M, Kazusaka A, Fujita S. Polymorphism in
diazepam metabolism in Wistar rats. JPharm Sci 2004;93:1271-1278.

130.

Saito K, Sakai N, Kim HS, Ishizuka M, Kazusaka A, Fujita S. Strain differences
in diazepam metabolism at its three metabolic sites in sprague-dawley, brown
norway, dark agouti, and wistar strain rats. DrugMetab Dispos 2004;32:959-965.

131.

Gao G, Li Y, Fant J, Crosson CE, Becerra SP, Ma JX. Difference in ischemic
regulation of vascular endothelial growth factor and pigment epithelium—derived
factor in brown norway and sprague dawley rats contributing to different
susceptibilities to retinal neovascularization. Diabetes 2002;51:1218-1225.

132.

Holscher C. Different strains of rats show different sensitivity to block of longterm potentiation by nitric oxide synthase inhibitors. Eur J Pharmacol
2002;457:99-106.

133.

Wang X, Cupples WA. Interaction between nitric oxide and renal myogenic
autoregulation in normotensive and hypertensive rats. Can J Physiol Pharmacol
2001;79:238-245.

134.

Sehi M, Flanagan JG, Zeng L, Cook RJ, Trope GE. Relative change in diurnal
mean ocular perfusion pressure: a risk factor for the diagnosis of primary openangle glaucoma. Invest Ophthalmol Vis Sci 2005;46:561-567.

135.

Mayor-Torroglosa S, De la Villa P, Rodriguez ME, et al. Ischemia results 3
months later in altered ERG, degeneration of inner layers, and deafferented

164
tectum: neuroprotection with brimonidine. Invest Ophthalmol Vis Sci
2005;46:3825-3835.
136.

Bayer AU, Neuhardt T, May AC, et al. Retinal morphology and ERG response in
the DBA/2NNia mouse model of angle-closure glaucoma. Invest Ophthalmol Vis
Sri 2001;42:1258-1265.

137.

Drusano GL, Liu W, Perkins R, et al. Determination of robust ocular
pharmacokinetic parameters in serum and vitreous humor of albino rabbits
following systemic administration of ciprofloxacin from sparse data sets by using
IT2S, a population pharmacokinetic modeling program. Antimicrob Agents
Chemother 1995;39:1683-1687.

138.

Mayers M, Rush D, Madu A, Motyl M, Miller MH. Pharmacokinetics of
amikacin and chloramphenicol in the aqueous humor of rabbits. Antimicrob
Agents Chemother 1991;35:1791-1798.

139.

Quigley HA, Broman AT. The number of people with glaucoma worldwide in
2010 and 2020. Br J Ophthalmol2006;90:262-267'.

140.

Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ.
Retinal ganglion cell death in experimental glaucoma and after axotomy occurs
by apoptosis. Invest Ophthalmol Vis Sci 1995;36:774-786.

141.

Colasanti BK, Brown RE, Craig CR. Ocular hypotension, ocular toxicity, and
neurotoxicity in response to marihuana extract and cannabidiol. Gen Pharmacol
1984;15:479-484.

142.

Colasanti BK, Craig CR, Allara RD. Intraocular pressure, ocular toxicity and
neurotoxicity after administration of cannabinol or cannabigerol. Exp Eye Res
1984;39:251-259.

143.

Colasanti BK, Powell SR, Craig CR. Intraocular pressure, ocular toxicity and
neurotoxicity after administration of delta 9-tetrahydrocannabinol or
cannabichromene. Exp Eye Res 1984;38:63-71.

144.

Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral
receptor for cannabinoids. Nature 1993;365:61-65.

145.

Rinaldi-Carmona M, Barth F, Heaulme M, et al. SR141716A, a potent and
selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994;350:240244.

146.

Rinaldi-Carmona M, Barth F, Millan J, et al. SR 144528, the first potent and
selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther
1998;284:644-650.

147.

Green K, Pederson JE. Effect of 1 -tetrahydrocannabinol on aqueous dynamics
and ciliary body permeability in the rabbit. Exp Eye Res 1973;15:499-507.

148.

Green K, Bigger JF, Kim K, Bowman K. Cannabinoid penetration and chronic
effects in the eye. Exp Eye Res 1977;24:197-205.

149.

Green K, Wynn H, Bowman KA. A comparison of topical cannabinoids on
intraocular pressure. Exp Eye Res 1978;27:239-246.

150.

Merritt JC, Perry DD, Russell DN, Jones BF. Topical delta 9tetrahydrocannabinol and aqueous dynamics in glaucoma. J Clin Pharmacol
1981;21:467S-471S.

151.

Muchtar S, Almog S, Torracca MT, Saettone MF, Benita S. A submicron
emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: effect on intraocular
pressure in rabbits. Ophthalmic Res 1992;24:142-149.

152.

Jarvinen T, Pate DW, Laine K. Cannabinoids in the treatment of glaucoma.
Pharmacol Ther 2002;95:203-220.

153.

Boyd ST, Fremming BA. Rimonabant-a selective CB1 antagonist. Ann
Pharmacother 2005;39:684-690.

154.

Chien FY, Wang RF, Mittag TW, Podos SM. Effect of WIN 55212-2, a
cannabinoid receptor agonist, on aqueous humor dynamics in monkeys. Arch
Ophthalmol 2003;121:87-90.

155.

Martin BR. Cellular effects of cannabinoids. Pharmacol Rev 1986;38:45-74.

156.

Porcella A, Maxia C, Gessa GL, Pani L. The synthetic cannabinoid WIN55212-2
decreases the intraocular pressure in human glaucoma resistant to conventional
therapies. EurJNeurosci 2001;13:409-412.

157.

Maurice DM. Drug delivery to the posterior segment from drops. Surv
Ophthalmol2002;47 Suppl l:S41-52.

167
158.

Casson RJ, Chidlow G, Wood JP, Vidal-Sanz M, Osborne NN. The effect of
retinal ganglion cell injury on light-induced photoreceptor degeneration. Invest
Ophthalmol Vis Sci 2004;45:685-693.

159.

Shen Y, Liu XL, Yang XL. N-methyl-D-aspartate receptors in the retina. Mol
Neurobiol 2006;34:163-179.

160.

Jakobs TC, Ben Y, Masland RH. Expression of mRNA for glutamate receptor
subunits distinguishes the major classes of retinal neurons, but is less specific for
individual cell types. Mol Vis 2007;13:933-948.

161.

Massey SC, Miller RF. N-methyl-D-aspartate receptors of ganglion cells in rabbit
retina. JNeurophysiol 1990;63:16-30.

162.

Fernandez-Lopez D, Martinez-Orgado J, Nunez E, et al. Characterization of the
neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model
of hypoxic-ischemic brain damage in newborn rats. Pediatr Res 2006;60:169-173.

163.

Gilbert GL, Kim HJ, Waataja JJ, Thayer SA. Delta9-tetrahydrocannabinol
protects hippocampal neurons from excitotoxicity. Brain Res 2007;1128:61-69.

164.

Shouman B, Fontaine RH, Baud O, et al. Endocannabinoids potently protect the
newborn brain against AMPA-kainate receptor-mediated excitotoxic damage. Br
J Pharmacol 2006; 148:442-451.

168
165.

Chen J, Errico SL, Freed WJ. Reactive oxygen species and p38 phosphorylation
regulate the protective effect of Delta9-tetrahydrocannabinol in the apoptotic
response to NMDA. Neurosci Lett 2005;389:99-103.

166.

Ohno-Shosaku T, Hashimotodani Y, Ano M, Takeda S, Tsubokawa H, Kano M.
Endocannabinoid signalling triggered by NMDA receptor-mediated calcium entry
into rat hippocampal neurons. J Physiol 2007;584:407-418.

167.

Ohzeki T, Machida S, Takahashi T, Ohtaka K, Kurosaka D. The Effect of
intravitreal N-methyl-DL-aspartic acid on the electroretinogram in Royal College
of surgeons rats. Jpn J Ophthalmol 2007;51:165-174.

168.

Kerrigan LA, Zack DJ, Quigley HA, Smith SD, Pease ME. TUNEL-positive
ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol
1997;115:1031-1035.

169.

Okisaka S, Murakami A, Mizukawa A, Ito J. Apoptosis in retinal ganglion cell
decrease in human glaucomatous eyes. Jpn J Ophthalmol 1997;41:84-88.

170.

Quigley HA. Ganglion cell death in glaucoma: pathology recapitulates ontogeny.
Aust NZ J Ophthalmol 1995;23:85-91.

171.

Guo L, Salt TE, Maass A, et al. Assessment of neuroprotective effects of
glutamate modulation on glaucoma-related retinal ganglion cell apoptosis in vivo.
Invest Ophthalmol Vis Sci 2006;47:626-633.

169
172.

Nicoletti F, Bruno V, Copani A, Casabona G, Knopfel T. Metabotropic glutamate
receptors: a new target for the therapy of neurodegenerative disorders? Trends
Neurosci 1996;19:267-271.

173.

Pin JP, Duvoisin R. The metabotropic glutamate receptors: structure and
functions. Neuropharmacology 1995;34:1-26.

174.

Chaudhary P, Ahmed F, Sharma SC. MK801-a neuroprotectant in rat
hypertensive eyes. Brain Res 1998;792:154-158.

175.

Kim SH, Won SJ, Mao XO, Jin K, Greenberg DA. Molecular mechanisms of
cannabinoid protection from neuronal excitotoxicity. Mol Pharmacol
2006;69:691-696.

176.

Grass GM, Robinson JR. Relationship of chemical structure to corneal penetration
and influence of low-viscosity solution on ocular bioavailability. J Pharm Sci
1984;73:1021-1027.

177.

Munemasa Y, Ohtani-Kaneko R, Kitaoka Y, et al. Pro-apoptotic role of c-Jun in
NMDA-induced neurotoxicity in the rat retina. J Neurosci Res 2006;83:907-918.

178.

Nickells RW. The molecular biology of retinal ganglion cell death: caveats and
controversies. Brain Res Bull 2004;62:439-446.

179.

Lin HJ, Lai CC, Lee Chao PD, et al. Aloe-emodin metabolites protected Nmethyl-d-aspartate-treated retinal ganglion cells by Cu-Zn superoxide dismutase.
J Ocul Pharmacol Ther 2007;23:152-171.

170
180.

Arici MK, Sayici M, Toker M, Erdogan H, Topalkara A. A short term study of the
additive effect of timolol and brimonidine on intraocular pressure. Eye
2002;16:39-43.

181.

Larsson LI. Aqueous humor flow in normal human eyes treated with brimonidine
and timolol, alone and in combination. Arch Ophthalmol 2001 ;119:492-495.

182.

Lee DA, Gornbein JA. Effectiveness and safety of brimonidine as adjunctive
therapy for patients with elevated intraocular pressure in a large, open-label
community trial. J Glaucoma 2001;10:220-226.

183.

Yuksel N, Altintas O, Karabas L, Alp B, Caglar Y. The short-term effect of
adding brimonidine 0.2% to timolol treatment in patients with open-angle
glaucoma. Ophthalmologica 1999;213:228-233.

184.

Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment
Study: baseline factors that predict the onset of primary open-angle glaucoma.
Arch Ophthalmol 2002;120:714-720; discussion 829-730.

185.

Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the
Collaborative Initial Glaucoma Treatment Study comparing initial treatment
randomized to medications or surgery. Ophthalmology 2001;108:1943-1953.

186.

Aim A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005%

latanoprost applied once daily, evening or morning. A comparison with timolol.
Scandinavian Latanoprost Study Group. Ophthalmology 1995;102:1743-1752.

171
187.

Aung T, Wong HT, Yip CC, Leong JY, Chan YH, Chew PT. Comparison of the
intraocular pressure-lowering effect of latanoprost and timolol in patients with
chronic angle closure glaucoma: a preliminary study. Ophthalmology
2000;107:1178-1183.

188.

Diestelhorst M, Roters S, Krieglstein GK. The effect of latanoprost 0.005% once
daily versus 0.0015% twice daily on intraocular pressure and aqueous humour
protein concentration in glaucoma patients. A randomized, double-masked
comparison with timolol 0.5%. Graefes Arch Clin Exp Ophthalmol 1997;235:2026.

189.

Hass I, Drance SM. Comparison between pilocarpine and timolol on diurnal
pressures in open-angle glaucoma. Arch Ophthalmol 1980;98:480-481.

190.

Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M. A comparison of
latanoprost and timolol in primary open-angle glaucoma and ocular hypertension.
A 12-week study. Arch Ophthalmol 1996; 114:929-932.

191.

Ozturk F, Ermis SS, Inan UU, Asagidag A, Yaman S. Comparison of the efficacy
and safety of dorzolamide 2% when added to brimonidine 0.2% or timolol
maleate 0.5% in patients with primary open-angle glaucoma. J Ocul Pharmacol
Ther 2005;21:68-74.

192.

Palkama A, Uusitalo H, Raij K, Uusitalo R. Comparison of the effects of
adrenergic agonists and alpha-, beta 1-, beta 2-antagonists on the intraocular

pressure and adenylate cyclase activity in the ciliary processes of the rabbit. Acta
Ophthalmol (Copenh) 1985;63:9-15.
193.

Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K. A 1 -year
study of brimonidine twice daily in glaucoma and ocular hypertension. A
controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study
Group. Arch Ophthalmol 1997;115:847-852.

194.

Stewart RH, Kimbrough RL, Ward RL. Betaxolol vs timolol. A six-month
double-blind comparison. Arch Ophthalmol 1986;104:46-48.

195.

Tomita G, Araie M, Kitazawa Y, Tsukahara S. A three-year prospective,
randomized and open comparison between latanoprost and timolol in Japanese
normal-tension glaucoma patients. Eye 2004;18:984-989.

196.

Vasquez C, Lewis DL. The CB1 cannabinoid receptor can sequester G-proteins,
making them unavailable to couple to other receptors. JNeurosci 1999;19:92719280.

197.

Fuchsjager-Mayrl G, Wally B, Rainer G, et al. Effect of dorzolamide and timolol
on ocular blood flow in patients with primary open angle glaucoma and ocular
hypertension. Br J Ophthalmol 2005;89:1293-1297.

198.

Josefsson A, Sigurdsson SB, Bang K, Eysteinsson T. Dorzolamide induces
vasodilatation in isolated pre-contracted bovine retinal arteries. Exp Eye Res
2004;78:215-221.

173
199.

Kiss B, Dallinger S, Findl O, Rainer G, Eichler HG, Schmetterer L.
Acetazolamide-induced cerebral and ocular vasodilation in humans is independent
of nitric oxide. Am J Physiol 1999;276:R1661-1667.

200.

Reber F, Gersch U, Funk RW. Blockers of carbonic anhydrase can cause increase
of retinal capillary diameter, decrease of extracellular and increase of intracellular
pH in rat retinal organ culture. Graefes Arch Clin Exp Ophthalmol 2003;241:14-0148.

201.

Maor D, Treves T, Korczyn AD. Lack of effect of cannabinoids on carbonic
anhydrase. J Neural Transm 1980;49:205-206.

202.

Lee DA, Topper JE, Brubaker RF. Effect of clonidine on aqueous humor flow in
normal human eyes. Exp Eye Res 1984;38:239-246.

203.

Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on
aqueous humor dynamics in human eyes. Arch Ophthalmol 1995;113:1514-1517.

204.

Toris CB, Tafoya ME, Camras CB, Yablonski ME. Effects of apraclonidine on
aqueous humor dynamics in human eyes. Ophthalmology 1995;102:456-461.

205.

Djellas Y, Antonakis K, Le Breton GC. Shifts in the affinity distribution of one
class of seven-transmembrane receptors by activation of a separate class of seventransmembrane receptors. Biochem Pharmacol 2000;59:1521-1529.

206.

Hodge WG, Lachaine J, Steffensen I, et al. The efficacy and harm of
prostaglandin analogues for IOP reduction in glaucoma patients compared to

174
dorzolamide and brimonidine: a systematic review. Br J Ophthalmol 2008;92:712.
207.

Koz OG, Ozsoy A, Yarangumeli A, Kose SK, Kural G. Comparison of the effects
of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month
clinical trial. Acta Ophthalmol Scand 2007;85:838-843.

208.

Drago F, Valzelli S, Emmi I, Marino A, Scalia CC, Marino V. Latanoprost exerts
neuroprotective activity in vitro and in vivo. Exp Eye Res 2001;72:479-486.

209.

Kudo H, Nakazawa T, Shimura M, et al. Neuroprotective effect of latanoprost on
rat retinal ganglion cells. Graefes Arch Clin Exp Ophthalmol 2006;244:10031009.

210.

Husain S, Whitlock NA, Rice DS, Crosson CE. Effects of latanoprost on rodent
intraocular pressure. Exp Eye Res 2006;83:1453-1458.

211.

Bui BV, Fortune B. Ganglion cell contributions to the rat full-field
electroretinogram. J Physiol 2004;555:153-173.

212.

Sharma S, Ball SL, Peachey NS. Pharmacological studies of the mouse cone
electroretinogram. Vis Neurosci 2005;22:631-636.

213.

Xu L, Ball SL, Alexander KR, Peachey NS. Pharmacological analysis of the rat
cone electroretinogram. Vis Neurosci 2003;20:297-306.

175

VITA
Sandeep Samudre
501 Ruby Court, Chesapeake, VA 23320, Email: SandeepSamudre@gmail.com
Education
Doctor of Philosophy - 2008, Ocular Pharmacology
Eastern Virginia Medical School - Old Dominion University, Norfolk, VA
Masters in Public Health - 2001, Health Care Management,
Eastern Virginia Medical School - Old Dominion University, Norfolk, VA
Bachelor of Science - 1998, Biology, minor in Chemistry, Old Dominion University,
Norfolk, VA
Work Experience
2007 - Current, Post Doctoral Fellow, Ocucure Therapeutics Inc., Roanoke, VA and
Eastern Virginia Medical School, Norfolk, VA
2004 - Current, Professor of Biology, Department of Math and Sciences,
Tidewater Community College, Portsmouth, VA
Honors and Awards {selected from a list of 12)
Young Scientist Travel Award - American Society of Pharmacology and Experimental
Therapeutics' annual Experimental Biology meeting, San Diego, CA, 2008.
Patents
August 2006 - Initial application for a use patent filed with Eastern Virginia Medical
School - Office of Technology Transfer for endocannabinoid analog, 0-1812.
Presentations/Abstracts {selectedfrom a list of 27)
Sandeep Samudre, Frank A Lattanzio, Jr., Billy R Martin, Ivan Castillo, Alireza
Hosseini, Mauro Frazier, and Patricia B Williams, Ocular Pharmacokinetics and
Pharmacodynamics of Synthetic Cannabinoid, 0-1812, in a Perfused Rat Eye Model
FASEB J. 21:566.6
Publications {selectedfrom a list of 7)
Oltmanns, M. and Samudre, S.S., Castillo, I.G., Hosseini, A., Lichtman, A., Allen, R.C.,
Lattanzio, F.A., Williams, P.B. Topical WIN 55-212-2 Alleviates Intraocular
Hypertension in Rats through a CB1 Receptor Mechanism of Action. J Ocul Pharmacol
Ther. 2008;24:104-115
Research Grants
Richmond Eye and Ear Foundation, Richmond, VA, 08/01/05 - 07/31/07
Role: Co-investigator, Dr. Patricia B. Williams (PI)

